<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004062.pub2" GROUP_ID="UPPERGI" ID="480200010718494684" MERGED_FROM="" MODIFIED="2010-09-21 21:25:21 +0200" MODIFIED_BY="Karin Dearness" REVIEW_NO="19" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.1">
<COVER_SHEET MODIFIED="2010-09-21 21:25:21 +0200" MODIFIED_BY="Karin Dearness">
<TITLE MODIFIED="2009-06-02 14:01:29 +0100" MODIFIED_BY="Cathy Bennett">Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer</TITLE>
<CONTACT MODIFIED="2010-09-21 21:25:21 +0200" MODIFIED_BY="Karin Dearness"><PERSON ID="16655" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Javier</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Gisbert</LAST_NAME><POSITION>Gastroenterology Unit</POSITION><EMAIL_1>gisbert@meditex.es</EMAIL_1><ADDRESS><ORGANISATION>Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)</ORGANISATION><CITY>Madrid</CITY><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>0034913093911</PHONE_1><FAX_1>0034914022299</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-21 21:25:21 +0200" MODIFIED_BY="Karin Dearness"><PERSON ID="16655" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Javier</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Gisbert</LAST_NAME><POSITION>Gastroenterology Unit</POSITION><EMAIL_1>gisbert@meditex.es</EMAIL_1><ADDRESS><ORGANISATION>Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)</ORGANISATION><CITY>Madrid</CITY><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>0034913093911</PHONE_1><FAX_1>0034914022299</FAX_1></ADDRESS></PERSON><PERSON ID="16677" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sam</FIRST_NAME><LAST_NAME>Khorrami</LAST_NAME><EMAIL_1>samkhorrami@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Gastroenterology</DEPARTMENT><ORGANISATION>Hospital de Son Dureta</ORGANISATION><CITY>Mallorca</CITY><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>34-915202254</PHONE_1><FAX_1>34-914022299</FAX_1></ADDRESS></PERSON><PERSON ID="16637" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Fernando</FIRST_NAME><LAST_NAME>Carballo</LAST_NAME><EMAIL_2>fcar@redeguias.net</EMAIL_2><ADDRESS><DEPARTMENT>Gastroenterology</DEPARTMENT><ORGANISATION>Hospital Virgen de la Arrixaca</ORGANISATION><CITY>Valencia</CITY><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>34-626 071199</PHONE_1><FAX_1>34-949 209216</FAX_1></ADDRESS></PERSON><PERSON ID="16635" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xavier</FIRST_NAME><LAST_NAME>Calvet</LAST_NAME><EMAIL_1>xcalvet@tauli.cat</EMAIL_1><MOBILE_PHONE>+34615890929</MOBILE_PHONE><ADDRESS><DEPARTMENT>Servei de Malalties Digestives</DEPARTMENT><ORGANISATION>Hospital de Sabadell &amp; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)</ORGANISATION><ADDRESS_1>Parc Taulí, s/n</ADDRESS_1><CITY>Sabadell</CITY><ZIP>08208</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>34 937231010</PHONE_1><FAX_1>34 937160646</FAX_1></ADDRESS></PERSON><PERSON ID="16654" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Emili</FIRST_NAME><LAST_NAME>Gené</LAST_NAME><POSITION>M.D., Ph.D.</POSITION><EMAIL_1>med011605@nacom.es</EMAIL_1><ADDRESS><DEPARTMENT>Servei de Medicina</DEPARTMENT><ORGANISATION>Hospital de Sabadell. Institut Universitary Parc Taulí. Universitat Autónoma de Barcelona</ORGANISATION><ADDRESS_1>Parc Talí s/n</ADDRESS_1><CITY>Sabadell</CITY><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>34-937231010</PHONE_1><FAX_1>34-937160646</FAX_1></ADDRESS></PERSON><PERSON ID="16645" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Enrique</FIRST_NAME><LAST_NAME>Dominguez-Muñoz</LAST_NAME><POSITION>M.D., Ph.D.</POSITION><EMAIL_1>enrique.dominguez.munoz@sergas.es</EMAIL_1><ADDRESS><DEPARTMENT>Gastroenterology</DEPARTMENT><ORGANISATION>Hospital Clinico Universitario</ORGANISATION><ADDRESS_1>Choupana s/n</ADDRESS_1><CITY>Santiago de Compostela (Coruña)</CITY><ZIP>15706</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>34 981 950 076</PHONE_1><PHONE_2>34 981 951 642</PHONE_2><FAX_1>34 981 951 692</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-07-23 16:45:04 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="10" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-21 21:25:21 +0200" MODIFIED_BY="Karin Dearness"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 21:25:21 +0200" MODIFIED_BY="Karin Dearness"><DATE DAY="21" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2009-07-23 16:45:31 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Searches, tables and figures last updated June 2009. Review declared stable by authors and no future updates planned.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-07-23 16:44:58 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-07-23 16:44:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-29 10:12:28 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-01-29 10:12:31 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="17" MONTH="1" YEAR="2005"/>
<DESCRIPTION>
<P>Minor update, new studies sought but none found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-01-29 10:12:45 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="8" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>New studies found and included or excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Supported in part by a Grant from the Instituto de Salud Carlos III (C03/02)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-07-23 14:56:29 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-07-23 14:25:53 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-07-23 13:40:20 +0100" MODIFIED_BY="[Empty name]">Antibiotics vs. acid suppression therapy (with or without long-term maintenance acid suppression therapy) for the prevention of recurrent bleeding from peptic ulcer</TITLE>
<SUMMARY_BODY MODIFIED="2009-07-23 14:25:53 +0100" MODIFIED_BY="[Empty name]">
<P>Peptic ulcers are caused by acidic stomach juices damaging the lining of the stomach (gastric ulcer) or upper small intestine (duodenal ulcer). This causes pain, indigestion and sometimes bleeding. Bleeding in the gut can be life-threatening. Several treatments aim to heal the ulcer and prevent future bleeding. These include acid-suppressing drugs and antibiotics to treat <I>Helicobacter pylori</I>, a bacterium that causes most peptic ulcers. The review found that, for people who have had a bleeding peptic ulcer caused by <I>Helicobacter pylori</I>, treatment with antibiotics more effectively prevents gastrointestinal re-bleeding than acid-suppressing drugs. Antibiotics when <I>Helicobacter pylori</I> infection is present are also cheaper and more convenient than long-term acid-suppressing drugs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-07-23 14:37:09 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-07-01 11:52:22 +0100" MODIFIED_BY="Cathy Bennett">
<P>Peptic ulcer is the main cause for upper gastrointestinal haemorrhage, and <I>Helicobacter pylori</I> (<I>H.pylor</I>i) infection is the main etiologic factor for peptic ulcer disease. Maintenance antisecretory therapy is the standard long-term treatment for patients with bleeding ulcers to prevent recurrent bleeding. The efficacy of <I>H. pylori</I> eradication for the prevention of rebleeding from peptic ulcer is unknown.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-07-01 11:52:26 +0100" MODIFIED_BY="Cathy Bennett">
<P>To compare the efficacy of <I>H. pylori</I> eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-07-23 14:37:09 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005 and October 2008, but no new trials were found.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-01 11:52:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>Controlled clinical trials comparing the efficacy of <I>H. pylori</I> eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-06-02 14:02:46 +0100" MODIFIED_BY="Cathy Bennett">
<P>Data extraction and quality assessment of studies was done by two reviewers. Study authors were contacted for additional information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-07-01 11:52:34 +0100" MODIFIED_BY="Cathy Bennett">
<P>Seven studies with a total of 578 patients were included in the first comparison: mean percentage of rebleeding in <I>H. pylori</I> eradication therapy group was 2.9%, and in the non-eradication therapy group without subsequent long-term maintenance antisecretory therapy it was 20% (OR 0.17, 95% CI 0.10 to 0.32; there was no statistical evidence of heterogeneity; NNT was 7, 95% CI 5 to 11). Three studies with a total of 470 patients were included in the second comparison: mean percentage of rebleeding in <I>H. pylori</I> eradication therapy group was 1.6%, and in non-eradication therapy group with long-term maintenance antisecretory therapy it was 5.6% (OR 0.24, 95% CI 0.09 to 0.67; heterogeneity was not demonstrated; NNT was 20, 95% CI 12 to 100). Subgroup analyses were carried out to examine the effect of NSAIDS and of excluding H.pylori eradication failures from the analyses.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-07-23 13:40:06 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment of <I>H. pylori</I> infection is more effective than antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. All patients with peptic ulcer bleeding should be tested for <I>H. pylori</I> infection, and eradication therapy should be prescribed to <I>H. pylori</I>-positive patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-07-23 14:56:29 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-07-01 11:53:20 +0100" MODIFIED_BY="Cathy Bennett">
<CONDITION MODIFIED="2009-01-29 11:53:53 +0000" MODIFIED_BY="Cathy Bennett">
<P>Upper gastrointestinal haemorrhage is a major cause of morbidity, mortality and medical care costs, with peptic ulcer being the most frequent source of bleeding (<LINK REF="REF-Laine-1994" TYPE="REFERENCE">Laine 1994</LINK>). It has been estimated that approximately 2-3% of duodenal ulcer patients who are not receiving antisecretory therapy are likely to develop haemorrhage during each year of follow-up study, giving a cumulative risk of haemorrhage after 5 years of approximately 10-14% (<LINK REF="REF-Mignon-1994" TYPE="REFERENCE">Mignon 1994</LINK>). Furthermore, patients whose ulcers have bled once have an increased risk of further rebleeding, compared with those with uncomplicated ulcer disease. Thus, among patients who present with a bleeding ulcer, approximately one-third will develop recurrent bleeding in the following 1-2 years, and 40-50% within the subsequent 10 years, if left untreated after ulcer healing (<LINK REF="REF-Petersen-1995" TYPE="REFERENCE">Petersen 1995</LINK>; <LINK REF="REF-Laine-1996" TYPE="REFERENCE">Laine 1996</LINK>). Furthermore, patients with bleeding ulcers account for an overall mortality rate that has remained around 5 to 10% for the past 50 years, despite improved medical and surgical treatments, the development of diagnostic and therapeutic endoscopy, and the availability of intensive care units (<LINK REF="REF-Gilbert-1990" TYPE="REFERENCE">Gilbert 1990</LINK>; <LINK REF="REF-Penston-1992" TYPE="REFERENCE">Penston 1992</LINK>; <LINK REF="REF-Laine-1994" TYPE="REFERENCE">Laine 1994</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-07-01 11:53:08 +0100" MODIFIED_BY="Cathy Bennett">
<P>Maintenance antisecretory therapy has been the standard long-term treatment for patients with bleeding ulcers to prevent recurrent bleeding, despite the fact that only two randomised studies have specifically examined such options in patients with peptic ulcer haemorrhage (<LINK REF="REF-Murray-1988" TYPE="REFERENCE">Murray 1988</LINK>; <LINK REF="REF-Jensen-1994" TYPE="REFERENCE">Jensen 1994</LINK>). The first study found no significant difference in the rate of recurrent bleeding between ranitidine maintenance therapy and placebo, but the number of bleeding episodes was so small that a treatment benefit could not be demonstrated (<LINK REF="REF-Murray-1988" TYPE="REFERENCE">Murray 1988</LINK>); the second study reported significantly fewer episodes of haemorrhage among patients taking ranitidine maintenance antisecretory regimen when compared with placebo (<LINK REF="REF-Jensen-1994" TYPE="REFERENCE">Jensen 1994</LINK>).</P>
<P>
<I>Helicobacter pylori</I> (<I>H. pylori</I>) infection is the main etiologic factor for peptic ulcer disease. However, although the role of this micro-organism on non-complicated peptic ulcer has been definitively established (<LINK REF="REF-Kuipers-1995" TYPE="REFERENCE">Kuipers 1995</LINK>), the precise relationship between <I>H. pylori</I> and complicated ulcer disease has hardly been studied (<LINK REF="REF-Gisbert-2003" TYPE="REFERENCE">Gisbert 2003</LINK>). <I>H. pylori</I> eradication has been demonstrated to dramatically reduce the rate of ulcer recurrence (<LINK REF="REF-Hopkins-1996" TYPE="REFERENCE">Hopkins 1996</LINK>). Therefore, it would seem logical to assume that <I>H. pylori</I> cure would also represent an effective strategy to prevent recurrence of ulcer bleeding. In 1994, the National Institutes of Health (NIH) Consensus Conference panel stated that, although preliminary studies indicate that cure of <I>H. pylori</I> infection prevents recurrent ulcer bleeding at rates equal to those of maintenance antisecretory therapy, until these studies can be confirmed, maintenance antisecretory "may be prudent" in such patients even after <I>H. pylori</I> eradication, in view of high risks associated with rebleeding (<LINK REF="REF-NIH-1994" TYPE="REFERENCE">NIH 1994</LINK>). Two years later, in 1996, the NIH Consensus Conference did not go any further, stating that "several trials indicate that <I>H. pylori</I> eradication also reduces the recurrence of ulcer complications, but the magnitude of this reduction remains to be firmly established" (<LINK REF="REF-Soll-1996" TYPE="REFERENCE">Soll 1996</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2009-07-01 11:53:20 +0100" MODIFIED_BY="Cathy Bennett">
<P>Although several authors have reported administration of <I>H. pylori</I> eradication treatment to patients with a history of peptic ulcer haemorrhage with the intention to prevent recurrence of bleeding, only a few studies have included a control group treated with "traditional" antisecretory non-eradicating therapy (followed or not by long-term maintenance antisecretory therapy). Furthermore, the number of patients included in these "eradication" studies has been small and, as the incidence of rebleeding episodes is relatively low (especially when antisecretory maintenance treatment is prescribed and follow-up limited), efficacy differences between groups may not be demonstrated due to a problem of statistical power of individual studies. Consequently, as the true efficacy of <I>H. pylori</I> eradication for the prevention of recurrent bleeding from peptic ulcer is unknown, it remains unclear whether maintenance antisecretory therapy must be continued or stopped in patients with a history of peptic ulcer haemorrhage and prior <I>H. pylori</I> eradication.</P>
<P>Finally, in addition to efficacy reasons, other relevant arguments may advocate the use of eradication therapy instead of maintenance antisecretory treatment. Firstly, the cost of antibiotic therapy is lower than long-term management by antisecretory drugs, mainly because the financial outlay for medication in the former approach is not cumulative as with the later. Secondly, one disadvantage of maintenance antisecretory therapy is the requirement for long-term compliance, which may not be sustained but wane, especially when symptoms are absent. And thirdly, it seems obvious that 7-10 days of antibiotic therapy is more convenient for the patients than many years of daily continuous antisecretory treatment.</P>
<P>With these antecedents, we aimed to perform a systematic review and a meta-analysis to compare the efficacy of <I>H. pylori</I> eradication therapy vs. antisecretory non-eradication therapy (followed or not by long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-07-01 11:53:23 +0100" MODIFIED_BY="Cathy Bennett">
<P>To compare the efficacy of <I>H. pylori</I> eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-07-23 14:45:01 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-07-01 11:54:02 +0100" MODIFIED_BY="Cathy Bennett">
<CRIT_STUDIES MODIFIED="2009-06-23 13:54:36 +0100" MODIFIED_BY="Cathy Bennett">
<P>Controlled clinical trials were eligible for inclusion in the review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-01 11:53:30 +0100" MODIFIED_BY="Cathy Bennett">
<UL>
<LI>Patients with a previous episode of peptic ulcer bleeding.</LI>
<LI>Patients were included if bleeding was severe enough to warrant hospitalisation, haematemesis or melena was evident, or a drop in haemoglobin level of more than 2 g/dL occurred.</LI>
<LI>The presence of an ulcer had to be documented endoscopically and no other potential bleeding source had to be found during initial evaluation.</LI>
<LI>Studies designed to follow patients up for less than 6 months were excluded.</LI>
<LI>Studies with all patients taking NSAIDs were excluded. <I>H. pylori</I> infection and NSAIDs seem to be mainly independent risk factors for peptic ulcer bleeding (<LINK REF="REF-Hawkey-2001" TYPE="REFERENCE">Hawkey 2001</LINK>). If all patients were taking NSAIDs prior to the bleeding episode, then the efficacy of <I>H. pylori</I> eradication for the prevention of recurrent bleeding in these patients would be masked, as most complications would be attributable to NSAIDs and therefore not prevented by eradicating the organism.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-01 11:54:02 +0100" MODIFIED_BY="Cathy Bennett">
<P>
<I>H. pylori</I> eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-06-23 13:55:07 +0100" MODIFIED_BY="Cathy Bennett">
<UL>
<LI>Recurrence of bleeding during follow-up (after prescribing eradication or antisecretory treatment) of more than 6 months.</LI>
<LI>Rebleeding during follow-up was assessed with the same criteria used for initial evaluation.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-01 11:54:05 +0100" MODIFIED_BY="Cathy Bennett">
<ELECTRONIC_SEARCHES MODIFIED="2009-06-02 15:39:52 +0100" MODIFIED_BY="Cathy Bennett">
<P>We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005, but no new trials were found. Searches in all databases were updated and re-run in October 2008. We did not confine our search to English language publications.</P>
<P>The Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE, Sensitivity maximising version, Ovid format (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>), was combined with the search terms in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> to identify randomised controlled trials in MEDLINE. The MEDLINE search strategy was adapted for use in the other databases searched.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-01 11:54:05 +0100" MODIFIED_BY="Cathy Bennett">
<P>Reference lists from the trials selected by electronic searching were handsearched to identify further relevant trials. Review articles examining the role of <I>H. pylori</I> infection on gastroduodenal haemorrhage were also searched to identify articles which met the inclusion criteria.<BR/>We also conducted a manual search of abstracts from 1995 to 2003 from the International Workshop on Gastroduodenal Pathology and <I>Helicobacter pylori</I> (EHPSG) published in Gut, the American Digestive Disease Week (DDW) published in Gastroenterology and the United European Gastroenterology Week (UEGW) published in Gut.<BR/>We included abstracts from congresses on the grounds that many negative studies are never published as a full paper, and the inclusion of abstracts thus prevents, or at least reduces, publication bias. Authors of trial reports published only as abstracts were contacted and asked to contribute full datasets or completed papers.<BR/>Abstracts of the articles selected in each of these multiple searches were reviewed and those meeting the inclusion criteria were recorded.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-07-23 14:45:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-07-01 11:54:15 +0100" MODIFIED_BY="Cathy Bennett">
<P>The Trials Search Co-ordinator for the Cochrane UGPD Group scanned the results of the electronic searches and removed all the obviously irrelevant references. These results were then independently assessed by two reviewers to ascertain if they were eligible for inclusion in the review. For the 2008 update, the authors reviewed the results of the updated searches and selected reports of studies for further scrutiny. The selection criteria were applied independently by two reviewers according to the pre-stated eligibility criteria, and where disagreements occurred they were resolved by consensus.</P>
<P>Only studies that clearly stated information about the number of treated patients and the number of patients with recurrent bleeding in each therapeutic group (<I>H. pylori</I> eradication group and non-eradication group) were included. The success of eradication therapy had to be based on the negative results of two tests or one test repeated twice during follow-up in order to make sure that <I>H. pylori</I> has been eliminated. <I>H. pylori</I> eradication success or failure had to be confirmed at least 4 weeks after antibiotic treatment has been completed.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-07-01 12:06:15 +0100" MODIFIED_BY="Cathy Bennett">
<P>The following variables were extracted in a predefined data extraction form (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'): author, year of publication, type of publication (complete article or abstract), type of participants (duodenal or gastric ulcer, or both), NSAID use previous to the inclusion in the study (yes/no; if yes, percentage of patients taking NSAIDs), intervention (<I>H. pylori</I> eradication treatment or antisecretory treatment; including drugs, dose, schedule and duration), maintenance antisecretory therapy (yes/no; if yes, drug, dose and schedule of administration), follow-up (months), quality score (see Jadad score in previous section, including items of randomisation, double blinding, and description of withdrawal/dropouts; concealment of allocation of the sequence of randomisation was also separately assessed), and rebleeding rate (raw numbers and percentages in each therapeutic group). Publications identified as duplicates were excluded; when more than one version of the same trial was retrieved, only the most recent data were considered. Extraction of studies was done independently by two reviewers. Discrepancies in the interpretation were resolved by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-07-01 12:16:07 +0100" MODIFIED_BY="Cathy Bennett">
<P>The quality of the studies was assessed using the score proposed by Jadad et al (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) based on 3 items: </P>
<OL>
<LI>Randomisation;</LI>
<LI>Double blinding; and</LI>
<LI>Description of withdrawals and dropouts.</LI>
</OL>
<P>The items are presented as questions to elicit yes or no answers. Points awarded for items 1 and 2 depended on the quality of the description of the methods to generate the sequence of randomisation and/or on the quality of the description of the method of double blinding. If the trial had been described as randomised and/or double blind, but there was no description of the methods used to generate the sequence of randomisation or the double blinding conditions, one point was awarded in each case. If the method of generating the sequence of randomisation and/or blinding had been described, one additional point was given to each item if the method was appropriate. A method to generate randomisation sequences was regarded as adequate if it allowed each study participant to have the same chance of receiving each intervention, and if the investigators could not predict which intervention was next. Double blinding was considered appropriate if it was stated or implied that neither the person doing the assessment nor the study participant could identify the intervention being assessed. Conversely, if the method of generating the sequence of randomisation and/or blinding was described but not appropriate, the relevant item was given zero points. The third item, withdrawals and dropouts, was awarded as zero points for a negative answer and one point for a positive. For a positive answer, the number of withdrawals and dropouts and the reasons had to be stated in each of the comparison groups. If there were no withdrawals, it should have been stated in the report.<BR/>Quality assessment of studies was done independently by two reviewers. Discrepancies in the interpretation were resolved by consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-06-18 11:20:46 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analysis was performed combining the Odds Ratios (OR) of the individual studies in a global OR, using both a random effect model (DerSimonian and Laird) and a fixed effect model (Peto method). Significance and 95% confidence intervals (95% CI) were provided for the combined OR. All calculations were performed with the Cochrane Collaboration's RevMan 4.2.<BR/>"Absolute risk reduction" (ARR; or "risk difference"), "relative risk reduction" (RRR), and "numbers needed to treat" (NNT) to prevent one episode of rebleeding were also calculated for the pooled data.</P>
</EFFECT_MEASURES>
<DATA_SYNTHESIS MODIFIED="2009-06-02 14:05:49 +0100" MODIFIED_BY="Cathy Bennett">
<P>The main outcome considered in this study was "percentage of patients having recurrence of bleeding" due to peptic ulcer.<BR/>Dropouts were considered as not having recurrent bleeding, as it is the most frequent outcome (see <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK>). In addition, it seems to be exceptional that patients having recurrent bleeding are lost for follow-up, as it is logical to assume that these patients will be finally included in the analysis<BR/>
</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-07-23 14:45:01 +0100" MODIFIED_BY="[Empty name]">
<P>Subanalyses were planned a priori depending on: Quality of the studies (based on quality score proposed by Jadad, see appropriate section), type of ulcer disease (duodenal/gastric), and duration of follow-up. Furthermore, subanalyses excluding those studies where rebleeding could be potentially explained by NSAID use were planned. Finally, assessment of potential role for <I>H. pylori</I> eradication failure, or recurrence of <I>H. pylori</I> infection, in patients with rebleeding were also planned.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-07-23 14:48:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-07-23 14:45:33 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES_DESCR MODIFIED="2009-07-23 14:45:33 +0100" MODIFIED_BY="[Empty name]">
<P>Seven studies finally fulfilled the inclusion criteria and contained data for the first planned comparison: <I>H. pylori</I> eradication therapy vs. non-eradication therapy with antisecretors without subsequent long-term maintenance antisecretory therapy (<LINK REF="STD-Arkkila-2003" TYPE="STUDY">Arkkila 2003</LINK>; <LINK REF="STD-Bataga-1997" TYPE="STUDY">Bataga 1997</LINK>; <LINK REF="STD-Graham-1993" TYPE="STUDY">Graham 1993</LINK>; <LINK REF="STD-Jaspersen-1995a" TYPE="STUDY">Jaspersen 1995a</LINK>; <LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>; <LINK REF="STD-Rokkas-1995" TYPE="STUDY">Rokkas 1995</LINK>; <LINK REF="STD-Vcev-1996" TYPE="STUDY">Vcev 1996</LINK>). Detailed characteristics of the studies are shown in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. Three-hundred and seventy five patients were included in the eradication therapy group, while 203 were included in the group receiving non-eradication therapy. Details of eradication and antisecretory treatment of included studies are summarized in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Three studies prescribed, as eradication regimen, a bismuth-based triple therapy, three other studies prescribed omeprazole-based dual therapy (omeprazole plus amoxicillin), and in one study both eradication regimens were used. These eradication regimens were administered for 10 to 14 days.</P>
<P>With respect to the second planned comparison (<I>H. pylori</I> eradication therapy vs. non-eradication therapy with antisecretors followed by long-term maintenance antisecretory therapy), three studies fulfilled the inclusion criteria (<LINK REF="STD-Riemann-1997" TYPE="STUDY">Riemann 1997</LINK>; <LINK REF="STD-Santander-1996" TYPE="STUDY">Santander 1996</LINK>; <LINK REF="STD-Sung-1997" TYPE="STUDY">Sung 1997</LINK>), detailed characteristics of them also being shown in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. Two-hundred and fifty seven patients were included in the eradication therapy group, while 213 received long-term maintenance antisecretory therapy. Details of eradication and antisecretory treatment of included studies are summarized in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. One study prescribed, as eradication regimen, a bismuth-based triple therapy, a second study prescribed omeprazole-based dual therapy (omeprazole plus amoxicillin), and in a third study both regimens were used. These eradication regimens were administered for 7 to 12 days. Antisecretory maintenance therapy with ranitidine 150 mg od was administered in two studies, while in a third study ranitidine 150 mg od or omeprazole 20 mg od was used as maintenance regimen.</P>
<P>No new included studies were found when the searches were run again in 2005 and 2008.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-07-01 11:54:39 +0100" MODIFIED_BY="Cathy Bennett">
<P>Excluded studies and respective causes of exclusion are summarized in the table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'. As shown in the table, causes of exclusion were: rebleeding not evaluated, less than six-month follow-up, no control group (all patients received <I>H. pylori</I> eradication therapy), no previous upper gastrointestinal bleeding, all patients received NSAIDs, no <I>H. pylori</I> eradication group, or control group included only <I>H. pylori</I>-negative patients or patients with unknown <I>H. pylori</I> status.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-23 14:46:19 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Assessment of study quality</HEADING>
<P>From the seven studies included in the first comparison (eradication therapy vs. non-eradication therapy without subsequent maintenance antisecretory therapy), two studies had a Jadad's quality score of 1, two more studies had a score of 2, and the three remaining studies had a score of 3 (see table of '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>') (a score &gt; or = 3 has been reported to indicate high quality; <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). All studies were randomised, but none of them were double-blinded. Allocation concealment was adequate in only two studies. One study was only in abstract form (and not in complete article form) (<LINK REF="STD-Vcev-1996" TYPE="STUDY">Vcev 1996</LINK>).</P>
<P>From the three studies included in the second comparison (<I>H. pylori</I> eradication therapy vs. non-eradication therapy with long-term maintenance antisecretory therapy), two studies had a Jadad's quality score of 2, and the remaining study had a score of 1 (see table of '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). This last study was controlled but not randomised, although it was stated that "prospective allocation into the <I>H. pylori</I> treatment regimen or the maintenance regimen was performed". None of the studies were double-blinded. Allocation concealment was adequate in only one study. All the studies were in complete article form.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-07-23 14:48:36 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1 - Eradication versus non eradication therapy (without long term maintenance antisecretory therapy)</HEADING>
<P>Seven studies with a total of 578 participants were included in the first comparison: mean percentage of rebleeding in <I>H. pylori</I> eradication therapy group was 2.9% (95% CI 0.10 to 0.32), and in the non-eradication therapy group without subsequent long-term maintenance antisecretory therapy it was 20% (95% CI 14 to 25%). The OR for this comparison was 0.17 (95% CI 0.10 to 0.32; P&lt;0.00001) using a fixed effect model, and 0.20 (95% CI 0.10 to 0.41; P&lt;0.00001) with a random effect model. Respective values for the RR were 0.22 (95% CI 0.12 to 0.40; P&lt;0.00001) and 0.26 (95% CI 0.14 to 0.48; P&lt;0.0001). There was no statistically significant heterogeneity (test for heterogeneity chi-square = 6.14, P=0.41). ARR or "risk difference" between the two groups was -0.15 (95% CI -0.21 to -0.09; P&lt;0.00001) with the fixed and (RD -0.17; 95% CI -0.26 to -0.08; P&lt;0.0002 <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) with the random effect models. The NNT with eradication therapy to prevent one episode of rebleeding, compared with non-eradication therapy, was 7 (95% CI 5 to 11) with the fixed effect model.</P>
<SUBSECTION>
<HEADING LEVEL="4">NSAID use</HEADING>
<P>One of the participants who had recurrence of haemorrhage in the study by Lai et al (<LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>) took NSAIDs at the time of rebleeding. Thus, subanalysis of the data excluding this patient resulted in rebleeding rate of 10/374 (2.7%, 95% CI 1.5 to 5%) in the group receiving <I>H. pylori</I> eradication therapy, OR of 0.16 (95% CI 0.09 to 0.30; P&lt;0.00001; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), RR of 0.20 (95% CI 0.11 to 0.38; P&lt;0.00001), ARR of -0.15 (95% CI -0.21 to -0.10; P&lt;0.00001), and NNT of 7 (95% CI 5 to 10) (fixed effect model).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>H. pylori</I> eradication failure</HEADING>
<P>In the study by Lai et al (<LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>), four out of the six participants with a rebleeding episode in the eradication treatment group had failed to eradicate <I>H. pylori</I> infection. In the study by Vcev et al (<LINK REF="STD-Vcev-1996" TYPE="STUDY">Vcev 1996</LINK>), all the three participants with recurrence of bleeding had failed to eradicate <I>H. pylori</I> infection with antibiotic therapy. Therefore, when these seven participants were excluded from the analysis, rebleeding occurred in 4/371 participants (1.1%, 95% CI 0.4 to 2.7%) in <I>H. pylori</I> eradication therapy group, OR was 0.10 (95% CI 0.05 to 0.19; P&lt;0.00001), RR 0.10 (95% CI 0.05 to 0.24; P&lt;0.00001), ARR -0.17 (95% CI -0.23 to -0.12;P&lt;0.00001; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), and NNT 6 (95% CI 3 to 7) (fixed effect model).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Recurrent bleeding considering high quality studies</HEADING>
<P>Of the studies included in Comparison 1, when only the three high quality studies (having a Jadad's quality score of 3) were included (see table of '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'), the Peto OR was 0.27; 95% CI 0.12 to 0.61, P= 0.002; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), RR 0.33 (95% CI 0.15 to 0.70; P=0.004), ARR -0.10 (95% CI -0.17 to -0.03; P=0.004), and NNT 10 (95% CI 6 to 33) (fixed effect model). </P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2 -  Eradication therapy versus long term maintenance anti-secretory therapy.</HEADING>
<P>Three studies with a total of 470 participants were included.  Mean percentage of rebleeding in <I>H. pylori</I> eradication therapy group was 1.6% (95% CI 0.6 to 3.9%), and in non-eradication therapy group with long-term maintenance antisecretory therapy it was 5.6% (95% CI 2.5 to 8.7%). The OR for this comparison was 0.24 (Peto OR 0.24; 95% CI 0.09 to 0.67; P=0.007; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) using a fixed effect model, and 0.26 (95% CI 0.08 to 0.80; P=0.02) with a random effect model. Respective values for RR were 0.27 (95% CI 0.09 to 0.77; P=0.01) and 0.28 (95% CI 0.10 to 0.82; P=0.02). There was no statistically significant heterogeneity (test for heterogeneity chi-square = 0.89, P=0.64). ARR or "risk difference" between the two groups was -0.05 (95% CI -0.08 to -0.01; P=0.02) with the fixed effect model, and -0.04 (95% CI -0.09 to -0.01; P=0.10) with the random effect model. The NNT with eradication therapy to prevent one episode of rebleeding, compared with long-term maintenance antisecretory therapy, was 20 (95% CI 12 to 100) with the fixed effect model.</P>
<SUBSECTION>
<HEADING LEVEL="4">NSAID use</HEADING>
<P>There were two participants suffering from recurrence of haemorrhage in the study by Riemann et al (<LINK REF="STD-Riemann-1997" TYPE="STUDY">Riemann 1997</LINK>), who had taken NSAIDs at the time of rebleeding (and they were <I>H. pylori</I>-negative). Subanalysis of the data excluding these two participants in the group receiving <I>H. pylori</I> eradication therapy were: rebleeding rate of 2/255 (0.78%, 95% CI 0.22 to 2.8%), RR of 0.16 (95% CI 0.04 to 0.58; P=0.005), OR of 0.14 (95% CI 0.05 to 0.43; P=0.0006; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), ARR of -0.05 (95% CI -0.09 to -0.02; P=0.003), and NNT of 20 (95% CI 11 to 50) (fixed effect model).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Recurrent bleeding considering high quality studies</HEADING>
<P>When trying to perform separate comparisons depending on the quality of studies in Comparison 2, all studies were classified as low quality (one of which was non-randomised (<LINK REF="STD-Santander-1996" TYPE="STUDY">Santander 1996</LINK>)), and therefore the influence of this variable could not be adequately assessed.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Additional planned subanalyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Type of ulcer disease</HEADING>
<P>In the first comparison, Eradication versus non eradication therapy (without long term maintenance antisecretory therapy), all but two studies included participants with only duodenal ulcers (see table of "<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>"), thus precluding adequate subanalysis of the results depending on the ulcer location (duodenal or gastric). Furthermore, in the second comparison, the three studies included participants with both duodenal and gastric ulcer, precluding again planned subanalysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of follow-up</HEADING>
<P>From the 10 studies included in the meta-analysis, all but two had a similar follow-up of 12 months (see table of "<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>"). Therefore, the influence of this variable on the outcome of the review (e.g. rate of rebleeding) could not be adequately assessed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Recurrence of <I>H. pylori</I> infection</HEADING>
<P>In the first comparison, one of the participants who had recurrence of haemorrhage in the study by Lai et al (<LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>) had recurrence of <I>H. pylori</I> infection at the time of rebleeding, while in the second comparison,  <I>H. pylori</I> recurrence occurred in the two participants having recurrence of haemorrhage in the study by Santander et al (<LINK REF="STD-Santander-1996" TYPE="STUDY">Santander 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rebleeding in participants with <I>H. pylori</I> eradication success</HEADING>
<P>Rebleeding in participants in whom <I>H. pylori</I> eradication was achieved (and did not receive maintenance antisecretory therapy) in studies included in the meta-analysis and in other uncontrolled studies from the literature are summarized in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Overall, from 1370 participants in whom <I>H. pylori</I> infection had been eradicated, mean rate of rebleeding (weighted mean) was 1.24% (95% CI 0.8 to 2%). However, as the follow-up time markedly varied among studies, this factor needs to be taken into account. Thus, follow-up periods in each study, measured in patient-years, and respective yearly bleeding (in patient-years<SUP>-1</SUP>), are also included in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. A total of 2179 patient-years of follow-up was calculated from all studies. A total of 17 rebleedings were observed among participants with <I>H. pylori</I> eradication success, yielding a yearly recurrence of 0.78% (95% CI 0.5 to 1.2) patient-years<SUP>-1</SUP>.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-07-23 14:56:29 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-07-23 14:51:19 +0100" MODIFIED_BY="[Empty name]">
<P>The main result of the present meta-analysis is that rebleeding is less frequent after <I>H. pylori</I> eradication therapy than after non-eradication antisecretory therapy, both with or without subsequent long-term maintenance antisecretory therapy, with ORs of about 0.17-0.25. This advantage is expressed by a NNT with eradication therapy to prevent one episode of rebleeding of only 7 when compared with ulcer healing treatment alone, and of 20 when compared with long-term maintenance antisecretory therapy (mainly because the risk of rebleeding with maintenance antisecretory therapy was relatively low), in agreement with results of previous report (<LINK REF="REF-Sharma-2001" TYPE="REFERENCE">Sharma 2001</LINK>).</P>
<P>The decision of whether maintenance antisecretory therapy must be continued or stopped in patients with a history of peptic ulcer haemorrhage and prior <I>H. pylori</I> eradication will depend on the true efficacy of <I>H. pylori</I> eradication for the prevention of recurrent bleeding. Thus, mean rebleeding rate in patients in whom <I>H. pylori</I> eradication was achieved (and did not receive maintenance antisecretory therapy) in studies included in the meta-analysis and in other uncontrolled studies from the literature (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>) was of only 1.24%. However, as the follow-up time markedly varied among studies (many of them being higher than 12 months), the risk of rebleeding is better expressed as "yearly" recurrence of bleeding, which was of only 0.78% patient-years<SUP>-1</SUP>.</P>
<P>In brief, probability of having recurrence of haemorrhage after <I>H. pylori</I> eradication is less than 1% per year, which arguments against the necessity or prescribing maintenance antisecretory therapy in these cases. Two recent randomised studies (<LINK REF="STD-Lai-1998" TYPE="STUDY">Lai 1998</LINK>; <LINK REF="STD-Pellicano-2001" TYPE="STUDY">Pellicano 2001</LINK>) have directly compared, after anti-<I>H. pylori</I> therapy had been prescribed and eradication confirmed, long-term maintenance antisecretory therapy vs. no treatment, reporting no differences in rebleeding rates, during a mean follow-up period of up to 47 months. Furthermore, the protective effect of <I>H. pylori</I> eradication seems to be maintained at least in the medium-term follow-up, as rebleeding rates of 0% have been reported even after 24 months (<LINK REF="STD-Amendola-1999" TYPE="STUDY">Amendola 1999</LINK>; <LINK REF="STD-Loperfido-2001" TYPE="STUDY">Loperfido 2001</LINK>; <LINK REF="STD-Macri-1998" TYPE="STUDY">Macri 1998</LINK>; <LINK REF="STD-Pellicano-2001" TYPE="STUDY">Pellicano 2001</LINK>). This observation seems to agree with the relatively low incidence of reinfection reported after <I>H. pylori</I> eradication, at least in developed countries, as discussed later.</P>
<P>Therefore, the results of our systematic review support the recommendation that it is unnecessary to continue antisecretory maintenance therapy in patients with a history of peptic ulcer bleeding and prior <I>H. pylori</I> eradication (<LINK REF="REF-Laine-1995" TYPE="REFERENCE">Laine 1995</LINK>; <LINK REF="REF-McColl-1995" TYPE="REFERENCE">McColl 1995</LINK>; <LINK REF="REF-Laine-1996" TYPE="REFERENCE">Laine 1996</LINK>). It must be emphasized, therefore, that in patients with previous peptic ulcer bleeding the success of <I>H. pylori</I> eradication should always be confirmed (<LINK REF="REF-McColl-1995" TYPE="REFERENCE">McColl 1995</LINK>; <LINK REF="REF-Howden-1998" TYPE="REFERENCE">Howden 1998</LINK>; <LINK REF="REF-van-Leerdam-2002" TYPE="REFERENCE">van Leerdam 2002</LINK>). In case of initial eradication failures, re-treatment should be prescribed. In clinical practice, several studies have demonstrated that <I>H. pylori</I> eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given (<LINK REF="REF-Gisbert-2002" TYPE="REFERENCE">Gisbert 2002</LINK>). The rare patients with a hypersecretory state or true idiopathic ulcers with coincident <I>H. pylori</I> infection may have recurrent bleeding despite <I>H. pylori</I> eradication (<LINK REF="REF-Laine-1995" TYPE="REFERENCE">Laine 1995</LINK>). However, this should be a very uncommon occurrence and, probably, does not justify the routine use of maintenance antisecretory therapy after <I>H. pylori</I> eradication (<LINK REF="REF-Laine-1995" TYPE="REFERENCE">Laine 1995</LINK>; <LINK REF="REF-Laine-1996" TYPE="REFERENCE">Laine 1996</LINK>).</P>
<P>Nevertheless, as it has been shown by the present meta-analysis, the prescription of <I>H. pylori</I> eradication therapy does not always prevent recurrence of bleeding, and several explanations could be suggested. Firstly, as antibiotic regimens are not 100% effective to treat <I>H. pylori</I> infection, eradication failures may explain, obviously, some of the rebleedings. For example, in the study by Lai et al (<LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>), 4 out of the 6 patients with a rebleeding episode in the eradication treatment group had failed to eradicate <I>H. pylori</I> infection; and in the study by Vcev et al (<LINK REF="STD-Vcev-1996" TYPE="STUDY">Vcev 1996</LINK>), all the three patients with recurrence of bleeding had failed to eradicate <I>H. pylori</I> infection with antibiotic therapy. Therefore, when these seven patients were excluded from the analysis, the rebleeding rate in the eradication therapy group was of only 1.1%.</P>
<P>Secondly, as recurrence of <I>H. pylori</I> infection seems to be an important cause of subsequent ulcer recurrence (and consequent rebleeding) (<LINK REF="REF-Gisbert-1998" TYPE="REFERENCE">Gisbert 1998</LINK>), the study of incidence of the organism's recurrence represents an important issue, as high reinfection rate offsets the expected beneficial effects of <I>H. pylori</I> eradication. In the comparison, one of the patients who had recurrence of haemorrhage in the study by Lai et al (<LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>) had recurrence of <I>H. pylori</I> infection at the time of rebleeding, while in the second comparison <I>H. pylori</I> recurrence occurred in the two patients having recurrence of haemorrhage in the study by Santander et al (<LINK REF="STD-Santander-1996" TYPE="STUDY">Santander 1996</LINK>). Other studies have also reported rebleeding only in patients with reinfection (<LINK REF="STD-Jaspersen-1995b" TYPE="STUDY">Jaspersen 1995b</LINK>). Fortunately, recurrence of <I>H. pylori</I> infection seems to be a relatively infrequent event in developed countries (<LINK REF="REF-Cutler-1993" TYPE="REFERENCE">Cutler 1993</LINK>; <LINK REF="REF-Forbes-1994" TYPE="REFERENCE">Forbes 1994</LINK>; <LINK REF="REF-Elta-1994" TYPE="REFERENCE">Elta 1994</LINK>; <LINK REF="REF-Bell-1996" TYPE="REFERENCE">Bell 1996</LINK>; <LINK REF="REF-Xia-1997" TYPE="REFERENCE">Xia 1997</LINK>; <LINK REF="REF-Gisbert-1998" TYPE="REFERENCE">Gisbert 1998</LINK>) and, therefore, initial <I>H. pylori</I> eradication is likely to confer long-term protection from rebleeding. Nevertheless, in countries where the rate of reinfection is higher, rebleeding may be a relevant problem even in patients with initial successful eradication.</P>
<P>Thirdly, NSAID intake probably explains a major percentage of rebleedings occurring despite <I>H. pylori</I> eradication. The use of these drugs at the time of rebleeding seemed to explain some of the episodes in the studies included in this meta-analysis (<LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>; <LINK REF="STD-Riemann-1997" TYPE="STUDY">Riemann 1997</LINK>), and also in other studies (<LINK REF="STD-Huellin-1998" TYPE="STUDY">Huellin 1998</LINK>). Although excluding from the analysis those patients with NSAID use will give us more strict data about the true role of <I>H. pylori</I> eradication in the prevention of recurrent bleeding, in clinical practice a relevant group of patients will probably take these drugs. Because clinical research, unlike basic science research, has clinical practicality as its foundation and not pure knowledge, we must probably accept the real results (including patients taking NSAIDs) as predictive of outcome for the population in question (<LINK REF="REF-Barthel-1997" TYPE="REFERENCE">Barthel 1997</LINK>).</P>
<P>Several advantages are associated with <I>H. pylori</I> eradication therapy, when compared with long-term maintenance antisecretory therapy in patients with previous peptic ulcer bleeding. Firstly, as previously shown, the first strategy is more effective than the second. It must be emphasized that the prevention of rebleeding with antisecretory maintenance therapy is, in any case, incomplete, since about 5-10% of the patients who receive this regimen have recurrent bleeding (<LINK REF="REF-Jensen-1994" TYPE="REFERENCE">Jensen 1994</LINK>; <LINK REF="REF-Laine-1996" TYPE="REFERENCE">Laine 1996</LINK>; <LINK REF="REF-Jaspersen-1995c" TYPE="REFERENCE">Jaspersen 1995c</LINK>). Furthermore, some data exist suggesting that continued administration of H2 receptor antagonist leads to pharmacological tolerance, with a decrease in its effect in controlling gastric acid secretion (<LINK REF="REF-Lachman-2000" TYPE="REFERENCE">Lachman 2000</LINK>). Secondly, one disadvantage of maintenance antisecretory therapy is the requirement for long-term compliance; patient compliance with antisecretors may not be sustained but wane, especially when symptoms are absent. Thirdly, it is obvious that 7-10 days of antibiotic therapy is more convenient for the patients than many years of continuous antisecretory treatment; therefore, even if these two forms of therapy would be equivalent (in terms of efficacy), it makes much more sense to choose the treatment that requires only a few days of therapy rather than the one that requires daily medication forever.</P>
<P>Finally, maintenance therapy is expensive. The cost of antibiotic therapy is lower than long-term management by antisecretory drugs, mainly because the financial outlay for medication in the former approach is not cumulative as with the later (<LINK REF="REF-Jonsson-1996" TYPE="REFERENCE">Jonsson 1996</LINK>; <LINK REF="REF-Sonnenberg-1999" TYPE="REFERENCE">Sonnenberg 1999</LINK>). The present meta-analysis clearly shows that the strategy of testing for <I>H. pylori</I> and treating if positive in patients with previous upper gastrointestinal haemorrhage secondary to peptic ulcer is considerably more effective than PPI maintenance therapy or no treatment. In addition, cost-effectiveness analysis underlines that this strategy is also the most favourable from a financial point of view even when wide variations of the current scenario are considered. Sharma et al (<LINK REF="REF-Sharma-2001" TYPE="REFERENCE">Sharma 2001</LINK>) compared treatment of <I>H. pylori</I> infection with other approaches to prevent recurrent ulcer haemorrhage to determine the least costly strategy. Decision model-based cost minimization analysis demonstrated that treatment of <I>H. pylori</I> infection was the least costly strategy unless the incidence of complicated recurrences after treatment was over 6%, or the cost of confirming eradication was over $741. Other authors have compared several strategies for the prevention of recurrent ulcer-related haemorrhage, from a cost-effectiveness perspective (<LINK REF="REF-Ofman-2002" TYPE="REFERENCE">Ofman 2002</LINK>). Decision analysis was used to compare the cost-per-recurrent haemorrhage prevented for 11 strategies over 1 year. The test/retest eradication strategy with maintenance PPI therapy for <I>H. pylori</I>-negative patients was most effective (prevention of recurrence in 96%). The test/retest eradication strategy with maintenance H2 receptor antagonist therapy for <I>H. pylori</I>-negative patients was least costly ($1070). The test/retest strategies were dominant with average cost-effectiveness ratios of 1118-1310 $/recurrent haemorrhage prevented with maintenance antisecretory therapy. These studies shows that the strategies based on the diagnosis and treatment of <I>H. pylori</I> are cost-effective for the prevention of recurrent ulcer-related haemorrhage because they result in fewer recurrent haemorrhages and fewer patients requiring antisecretory therapy. In summary, these studies emphasize that the relative "small" advantage in preventing rebleeding results in a substantial health-care cost saving.</P>
<P>Although, based on aforementioned arguments, it seems logical to test all patients with peptic ulcer bleeding for <I>H. pylori</I> infection, and to prescribe eradication therapy to <I>H. pylori</I>-positive patients, in clinical practice this strategy seems to have limited divulgation. Thus, it is disappointing that relatively few patients admitted to hospital with peptic ulcer haemorrhage appear to be tested for the infection or to be treated when present. In this respect, a recent study on a high number of such patients admitted to US hospitals found that only 56% were tested for <I>H. pylori</I> infection or appropriately treated for it (<LINK REF="REF-Hood-1999" TYPE="REFERENCE">Hood 1999</LINK>). These discouraging results regarding the implementation of <I>H. pylori</I> testing and treating have been confirmed in a review of case notes and endoscopy records of patients presenting to Auckland Hospital (<LINK REF="REF-Garrigan-1999" TYPE="REFERENCE">Garrigan 1999</LINK>). Finally, in another study aimed to investigate current management of ulcer haemorrhage in the Netherlands, it was found that <I>H. pylori</I> eradication was confirmed by only 64% of the physicians (<LINK REF="REF-van-Leerdam-2002" TYPE="REFERENCE">van Leerdam 2002</LINK>). In summary, it seems evident that management of patients with previous peptic ulcer haemorrhage is only partly in accordance with evidence-based medicine.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-07-01 11:57:23 +0100" MODIFIED_BY="Cathy Bennett">
<P>The present meta-analysis suffers from several possible limitations. Firstly, some limitation of the studies included need to be recognized: they were relatively small, none of them were double-blinded (the overall quality of the studies was low), and the follow-up period was limited to only one year in most cases. In this respect, it remains to be demonstrated that the beneficial effects of <I>H. pylori</I> eradication are maintained in the future, mainly because, as previously mentioned, <I>H. pylori</I> reinfection could be a problem in the long-term management. Secondly, the studies included in the meta-analysis were not homogeneous regarding <I>H. pylori</I> eradication regimen (and therefore regarding efficacy to successfully eradicate the organism); however, it seems that the prophylactic effect of <I>H. pylori</I> eradication on recurrence of haemorrhage depends mainly, or perhaps exclusively, on the capacity to eradicate the infection, which is supported by the encouraging results obtained with many different antibiotic regimens. Thirdly, antisecretory maintenance therapy also differed among different studies; thus, while some authors prescribed H2 receptor antagonist, others used PPI. Nevertheless, the findings of the meta-analysis were not statistically heterogeneous, thus suggesting that the combination of the study results is reasonable.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-07-23 14:56:29 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Quality scales and Cochrane reviews</HEADING>
<P>The Cochrane Handbook explicitly discourages the use of quality scales in Cochrane systematic reviews (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; section 8.3.3 and section 8.10.1)</P>
<P>However the present review evaluates the quality using the Jadad scale for historical reasons (quality assessment was performed in the previously published version of the review). None of the studies included in the meta-analysis were double-blinded and the overall quality of the studies included was low. Only three studies showed acceptable quality (score &gt; 3) based on Jadad scale while the remaining scored lower.</P>
</SUBSECTION>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-07-01 11:57:47 +0100" MODIFIED_BY="Cathy Bennett">
<IMPLICATIONS_PRACTICE MODIFIED="2009-07-01 11:57:40 +0100" MODIFIED_BY="Cathy Bennett">
<P>Treatment of <I>H. pylori</I> infection is more effective than antisecretory non-eradicating therapy (with or without long-term maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. When <I>H. pylori</I> eradication therapy is compared with ulcer healing treatment alone (without subsequent long-term maintenance antisecretory therapy), the magnitude of the beneficial effect of the first strategy is remarkable (NNT of only about 7, and even 6 if <I>H. pylori</I> eradication success is confirmed). However, when the comparison is performed against long-term maintenance antisecretory therapy, the "clinical impact" on the recurrence of bleeding is smaller (NNT of 20), mainly because the risk of rebleeding with maintenance therapy is relatively low. Nevertheless, in addition to efficacy, other relevant advantages of <I>H. pylori</I> eradication treatment, such as better compliance, better convenience, and lower cost, advised also for the use of antibiotic therapy. Finally, it seems unnecessary to continue antisecretory maintenance therapy in patients with a history of peptic ulcer bleeding and prior <I>H. pylori</I> eradication. Consequently, all patients with peptic ulcer bleeding should be tested for <I>H. pylori</I> infection, and eradication therapy should be prescribed to <I>H. pylori</I>-positive patients.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-07-01 11:57:47 +0100" MODIFIED_BY="Cathy Bennett">
<P>The findings of this review are relatively robust and unlikely to change with the result of further short- or medium-term follow-up trials. Although further short term trials of greater sample size would be useful, the main area of uncertainly is the assessment of the long-term beneficial results of <I>H. pylori</I> eradication and the role of the factors which could explain recurrence of bleeding despite <I>H. pylori</I> eradication success (especially NSAID use and <I>H. pylori</I> reinfection).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-06-02 10:17:04 +0100" MODIFIED_BY="Cathy Bennett">
<P>We thank Prof. D. Forman, Dr. E. Gardener, Dr. R. Laheij, Prof. P. Moayyedi and Dr. Savarino for their valuable advice and constructive comments on our review. We also appreciate Ms J. Lilleyman, Ms G. Sutherington and Ms I. Gordon in the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group for their helpful suggestions.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-01-29 12:26:13 +0000" MODIFIED_BY="Cathy Bennett">
<P>None known.<BR/>This study was not funded by any pharmaceutical company.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>JP Gisbert developed the protocol, performed the main search strategy, assessed eligibility, extracted the data, performed the statistical analyses (meta-analysis), and wrote the manuscript.<BR/>S Khorrami, X Calvet and E Gené were involved in the search strategy, checked eligibility and data extraction.<BR/>F Carballo and E Dominguez-Muñoz were involved in developing the protocol and provided senior support in overseeing the project. <BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-07-23 16:43:30 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-07-23 15:59:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arkkila-2003" MODIFIED="2009-07-23 15:09:10 +0100" MODIFIED_BY="[Empty name]" NAME="Arkkila 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-23 15:09:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arkkila PET, Seppälä K, Kosunen TU, Haapiainen R, Kivilaakso E, Sipponen P et al</AU>
<TI>Eradication of Helicobacter pylori improves healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>2149-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bataga-1997" NAME="Bataga 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Abstract&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bataga S, Bratu A, Bancu L, Haydu C, Torok I, Dudea C</AU>
<TI>The treatment in bleeding duodenal ulcer</TI>
<SO>Gut</SO>
<YR>1997</YR>
<VL>41(Suppl 3)</VL>
<PG>A167</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graham-1993" MODIFIED="2009-06-16 12:14:06 +0100" MODIFIED_BY="[Empty name]" NAME="Graham 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-06-16 12:14:06 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:14:06 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA</AU>
<TI>Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1993</YR>
<VL>28</VL>
<NO>11</NO>
<PG>939-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaspersen-1995a" MODIFIED="2009-06-16 12:15:09 +0100" MODIFIED_BY="[Empty name]" NAME="Jaspersen 1995a" YEAR="1995">
<REFERENCE MODIFIED="2009-06-16 12:15:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:15:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Hammar CH</AU>
<TI>Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>1</NO>
<PG>5-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lai-2000" MODIFIED="2009-07-23 15:09:49 +0100" MODIFIED_BY="[Empty name]" NAME="Lai 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-23 15:09:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:09:49 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lai KC, Hui WM, Wong WM, Wong BC, Hu WH, Ching CK, Lam SK</AU>
<TI>Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage - a long-term randomized, controlled study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>9</NO>
<PG>2225-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riemann-1997" MODIFIED="2009-06-16 12:15:38 +0100" MODIFIED_BY="[Empty name]" NAME="Riemann 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-06-16 12:15:38 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:15:38 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riemann JF, Schilling D, Schauwecker P, Wehlen G, Dorlars D, Kohler B, Maier M</AU>
<TI>Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>4</NO>
<PG>299-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rokkas-1995" MODIFIED="2009-06-16 12:15:55 +0100" MODIFIED_BY="[Empty name]" NAME="Rokkas 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-06-16 12:15:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:15:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N</AU>
<TI>Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santander-1996" MODIFIED="2009-07-23 15:10:27 +0100" MODIFIED_BY="[Empty name]" NAME="Santander 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-23 15:10:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santander C, Gravalos RG, Gomez-Cedenilla A, Cantero J, Pajares JM</AU>
<TI>Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1996</YR>
<VL>91</VL>
<NO>8</NO>
<PG>1549-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96322169"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sung-1997" MODIFIED="2009-07-23 15:11:31 +0100" MODIFIED_BY="[Empty name]" NAME="Sung 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-07-23 15:11:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:11:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sung JJ, Leung WK, Suen R, Leung VK, Chan FK, Ling TK et al</AU>
<TI>One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>12</NO>
<PG>2524-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vcev-1996" MODIFIED="2009-07-23 15:59:35 +0100" MODIFIED_BY="[Empty name]" NAME="Vcev 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-23 15:59:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vcev A, Horvat D, Rubinic M, Stimac D, Vceva A, Uravic M et al</AU>
<TI>Eradication of Helicobacter pylori reduces the possibility of rebleeding in duodenal ulcer disease</TI>
<TO>Eradikacija Helicobacter pylori smanjuje vjerojatnost ponovnog krvarenja iz duodenalnog ulkusa</TO>
<SO>Acta Facultatis Medicae Fluminensis</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>2</NO>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adamek-1994" MODIFIED="2009-06-16 12:22:29 +0100" MODIFIED_BY="[Empty name]" NAME="Adamek 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-06-16 12:22:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:22:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adamek RJ, Freitag M, Opferkuch W, Ruhl GH, Wegener M</AU>
<TI>Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1994</YR>
<VL>29</VL>
<NO>10</NO>
<PG>880-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altorjay-2000" MODIFIED="2009-07-23 15:12:31 +0100" MODIFIED_BY="[Empty name]" NAME="Altorjay 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-23 15:12:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Altorjay IF, Vitalis ZS, Szasz RR, Palatka KK, Udvardy MM</AU>
<TI>Immediate eradication of Helicobacter pylori infection seems to be beneficial compared to solely "PPI" treatment in the management of bleeding duodenal ulcer</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<PG>A1209</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amendola-1999" MODIFIED="2009-07-23 15:13:04 +0100" MODIFIED_BY="[Empty name]" NAME="Amendola 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-07-23 15:13:04 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:13:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amendola M, Farias R, Katz J, Luna P, Ianella M, Musi A et al</AU>
<TI>Absence of bleeding recurrence of peptic ulcer after long term follow-up of successful eradication of Helicobacter pylori</TI>
<SO>Acta Gastroenterologica Latinoamericana</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>2</NO>
<PG>47-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arkkila-2001" NAME="Arkkila 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arkkila PE, Farkkila MA, Kosunen T, Nuutinen HU, Sipponen P, Seppala K</AU>
<TI>The role of Helicobacter pylori eradication in bleeding peptic ulcer healing, relapse and rebleeding: a randomised controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>120 (suppl.1)</VL>
<PG>2962</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capurso-2001" MODIFIED="2009-07-23 15:02:26 +0100" MODIFIED_BY="[Empty name]" NAME="Capurso 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-23 15:02:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:02:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capurso G, Annibale B, Osborn J, D'Ambra G, Martino G, Lahner E, Delle Fave G</AU>
<TI>Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>6</NO>
<PG>821-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1997" NAME="Chan 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, Lee YT, Chan CS, Li EK, Woo J</AU>
<TI>Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>9083</NO>
<PG>975-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1998" MODIFIED="2009-07-23 15:02:41 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-07-23 15:02:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:02:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan FK, Sung JJ, Suen R, Lee YT, Wu JC, Leung WK, Chan HL, Lai AC, Lau JY, Ng EK, Chung SC</AU>
<TI>Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>12</NO>
<PG>1201-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2001" MODIFIED="2009-07-23 15:15:18 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-23 15:15:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:15:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK et al</AU>
<TI>Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>13</NO>
<PG>967-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2002a" MODIFIED="2009-07-23 15:15:40 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2002a" YEAR="2002">
<REFERENCE MODIFIED="2009-07-23 15:15:40 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:15:40 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T et al</AU>
<TI>Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9300</NO>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2002b" MODIFIED="2009-07-23 15:16:07 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2002b" YEAR="2002">
<REFERENCE MODIFIED="2009-07-23 15:16:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chan FKL, Wu JCY, Suen BY, Leung W, To KF, Hung LCT et al</AU>
<TI>Eradication of H. pylori to prevent recurrent ulcer complications associated with low-dose aspirin: A long-term cohort study</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>A86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1996" NAME="Chen 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chen CY, Chen CY, Chang TT, Lin XZ</AU>
<TI>Intravenous omeprazole plus antibiotics in Helicobacter-related peptic ulcer patients with major stigmata of recent hemorrhage - A preliminary report of a randomized controlled trial</TI>
<SO>Gut</SO>
<YR>1996</YR>
<VL>39 (Suppl.3)</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1998" NAME="Chen 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chen CY, Seu MZ, Lee SC</AU>
<TI>Short-term and long-term effect of new triple therapy in Helicobacter-related ulcer bleeding with major stigmata of recent hemorrhage</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>A89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Mario-1997" MODIFIED="2009-07-23 15:17:14 +0100" MODIFIED_BY="[Empty name]" NAME="Di Mario 1997" YEAR="">
<REFERENCE MODIFIED="2009-07-23 15:17:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Di Mario F, Salandin S, Kusstatscher S, Dal Bo N, Buda A, Franceschi M et al</AU>
<TI>Eradication of Helicobacter pylori (Hp) infection in preventing peptic ulcer bleeding</TI>
<SO>Gut</SO>
<YR>1997</YR>
<VL>41(Suppl.3)</VL>
<PG>A203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fakhreih-1995" MODIFIED="2009-07-23 15:16:49 +0100" MODIFIED_BY="[Empty name]" NAME="Fakhreih 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-07-23 15:16:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fakhreih S, Rahemi M, Dehbashi N, Firoozi MS, Keshavarz AA, Albborzi I et al</AU>
<TI>Eradication of Helicobacer pylori vs ranitidine maintenance therapy for prevention of duodenal ulcer rebleeding</TI>
<SO>Gut</SO>
<YR>1995</YR>
<VL>37 (Suppl.2)</VL>
<PG>A236</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gisbert-1995" MODIFIED="2009-07-23 15:17:44 +0100" MODIFIED_BY="[Empty name]" NAME="Gisbert 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-07-23 15:17:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Letter&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:17:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gisbert JP, Boixeda D, Hernandez Ranz F, Martin de Argila C</AU>
<TI>[Eradication of Helicobacter pylori and hemorrhagic recurrence of duodenal ulcer]</TI>
<SO>Revista Española de Enfermedades Digestivas</SO>
<YR>1995</YR>
<VL>87</VL>
<NO>12</NO>
<PG>910-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gisbert-1999" MODIFIED="2009-07-23 15:21:53 +0100" MODIFIED_BY="[Empty name]" NAME="Gisbert 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-07-23 15:21:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:21:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gisbert JP, Boixeda D, Aller R, de la Serna C, Sanz E, Martin de Argila C et al</AU>
<TI>[Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence]</TI>
<SO>Medicina Clínica (Barcelona)</SO>
<YR>1999</YR>
<VL>112</VL>
<NO>5</NO>
<PG>161-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsieh-2001" NAME="Hsieh 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsieh YH, Lin HJ, Tseng GY, Perng CL, Chang FY, Lee SD</AU>
<TI>A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection</TI>
<SO>Hepatogastroenterology</SO>
<YR>2001</YR>
<VL>48</VL>
<NO>40</NO>
<PG>1078-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huellin-1998" MODIFIED="2009-07-23 15:22:30 +0100" MODIFIED_BY="[Empty name]" NAME="Huellin 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-07-23 15:22:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Huelin Benitez J, Jimenez Perez M, Duran Campos A, España Contreras P, De la Cruz Lombardo J, Lozano Rey JM et al</AU>
<TI>Haemorrhagic relapse in duodenal ulcers after eradication of Helicobacter pylori</TI>
<SO>Gut</SO>
<YR>1998</YR>
<VL>43 (Suppl.2)</VL>
<PG>A101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaspersen-1994a" NAME="Jaspersen 1994a" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaspersen D, Korner T, Schorr W, Hammar C-H</AU>
<TI>Helicobacter pylori associated duodenum ulcer bleeding. Germ eradication with drugs is an useful therapy</TI>
<SO>Krankenhaus Arzt</SO>
<YR>1994</YR>
<VL>67</VL>
<NO>5</NO>
<PG>234-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaspersen-1994b" NAME="Jaspersen 1994b" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaspersen D, Korner T, Schorr W, Hammar C-H</AU>
<TI>Helicobacter-pylori-associated duodenal ulcer bleeding. Resuts of eradication treatment with omeprazole and amoxicillin</TI>
<SO>Munchener Medizinische Wochenschrift</SO>
<YR>1994</YR>
<VL>136</VL>
<NO>41</NO>
<PG>625-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaspersen-1995b" MODIFIED="2009-07-23 15:23:42 +0100" MODIFIED_BY="[Empty name]" NAME="Jaspersen 1995b" YEAR="1995">
<REFERENCE MODIFIED="2009-07-23 15:23:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:23:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaspersen D, Korner T, Schorr W, Brennenstuhl M, Hammar CH</AU>
<TI>Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study</TI>
<SO>Journal of Gastroenterology</SO>
<YR>1995</YR>
<VL>30</VL>
<NO>3</NO>
<PG>319-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krizman-1997" NAME="Krizman 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krizman I, Ribnikar M, Kozjek F, Primozic S</AU>
<TI>Comparative amoxicillin-azithromycin treatment of Helicobacter pylori positive patients with bleeding duodenal ulcer</TI>
<SO>Acta Pharmaceutica</SO>
<YR>1997</YR>
<VL>47</VL>
<NO>3</NO>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kung-1997" MODIFIED="2009-07-23 15:24:08 +0100" MODIFIED_BY="[Empty name]" NAME="Kung 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-07-23 15:24:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:24:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kung NN, Sung JJ, Yuen NW, Ng PW, Wong KC, Chung EC et al</AU>
<TI>Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>3</NO>
<PG>438-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labenz-1994" NAME="Labenz 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labenz J, Borsch G</AU>
<TI>Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse</TI>
<SO>Digestion</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>1</NO>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lai-1998" NAME="Lai 1998" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lai KC, Hui WM, Lam SK, Wong BCY, Chu KM, Wong WM, Hu WHC</AU>
<TI>Maintenance H2-antagonist is not necessary after eradication of Helicobacer pylori in bleeding peptic ulcers</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>A192</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lai-2000b" MODIFIED="2009-07-23 15:24:37 +0100" MODIFIED_BY="[Empty name]" NAME="Lai 2000b" YEAR="2000">
<REFERENCE MODIFIED="2009-07-23 15:24:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:24:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lai KC, Hui WM, Wong BC, Hu WH, Lam SK</AU>
<TI>Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>8</NO>
<PG>1071-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1998" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 16:43:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee CL, Tu TC, Wu CH, Chen TK, Chan CC, Huang SH, Lee SC</AU>
<TI>One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers</TI>
<SO>Journal of the Formosan Medical Association</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>11</NO>
<PG>733-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1999" NAME="Lee 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee CL, Wu CH, Chen TK, Tu TC, Chan CC, Lee SC</AU>
<TI>Maintenance anti-ulcer treatment is not necessary in patients with bleeding peptic ulcer after H. pylori eradication and ulcer healing</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45 (Suppl.3)</VL>
<PG>A116</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1999" MODIFIED="2009-06-16 12:29:22 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-06-16 12:29:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:29:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin HJ, Tseng GY, Hsieh YH, Perng CL, Lee FY, Chang FY, Lee SD</AU>
<TI>Will Helicobacter pylori affect short-term rebleeding rate in peptic ulcer bleeding patients after successful endoscopic therapy?</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>11</NO>
<PG>3184-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loperfido-2001" NAME="Loperfido 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Loperfido S, Priora R, Monica F, Salvat HH</AU>
<TI>Effect of Helicobacter pylori eradication on recurrence of bleeding duodenal ulcer and dyspeptic symptoms: A two-year prospective study</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>120 (Suppl.1)</VL>
<PG>A585</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macri-1998" MODIFIED="2009-06-16 12:29:43 +0100" MODIFIED_BY="[Empty name]" NAME="Macri 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-06-16 12:29:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:29:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macri G, Milani S, Surrenti E, Passaleva MT, Salvadori G, Surrenti C</AU>
<TI>Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>6</NO>
<PG>925-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martino-1998" NAME="Martino 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Martino G, Paoletti M, Annibale B, Marcheggiano A, Marignani M, Luzzi I, D'Ambra G, Iannoni C, Caprilli R, Delle Fave G</AU>
<TI>Duodenal ulcer and Helicobacter pylori: relapse and recurrence in a long-term study</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>A219</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pamos-1998" MODIFIED="2009-06-16 12:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Pamos 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-06-16 12:30:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pamos S, Lujan M, Canelles P, Orti E, Quiles F, Tome A et al</AU>
<TO>Erradicación del Helicobacter pylori y recidiva hemorrágica por ulcus gástrico</TO>
<SO>Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva</SO>
<YR>1998</YR>
<VL>90(supl.I)</VL>
<PG>136</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauly-1997" NAME="Pauly 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pauly MP, Nason DT, Spinka P, Pecha RE, Trudeau W</AU>
<TI>Antibiotic therapy does not eliminate the risk of rebleeding in Helicobacter pylori-positive patients with upper GI hemorrhage</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>112</VL>
<PG>A125</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pazzi-1996" NAME="Pazzi 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pazzi P, Dalla Libera M, La Froscia A, Carli G, Scagliaini R, Merighi A, Gullini S</AU>
<TI>Helicobacter pylori eradication reduces rebleeding rate in peptic ulcer disease</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<PG>A224</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pazzi-1999" NAME="Pazzi 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pazzi P, Scagliarini R, Gamberini S, Rizzo C, Gullini S</AU>
<TI>Helicobacter pylori (Hp) eradication and reduction of duodenal ulcer (DU) bleeding relapse: A 4-year follow-up study</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>116</VL>
<PG>A278</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pellicano-2001" MODIFIED="2009-07-23 15:25:33 +0100" MODIFIED_BY="[Empty name]" NAME="Pellicano 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-23 15:25:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:25:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pellicano R, Peyre S, Leone N, Repici A, De Angelis C, Rizzi R et al</AU>
<TI>The effect of the eradication of Helicobacter pylori infection on hemorrhage because of duodenal ulcer</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>3</NO>
<PG>222-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pica-1996" NAME="Pica 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pica R, Marigani M, D'Ambra G, Cavilia R, Antonelli G, Annibale B, Delle Fave G</AU>
<TI>One year H. pylori eradication in duodenal ulcer (DU) hypersecretory patients does not alter acid secretion but prevents ulcer relapse and bleeding</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>111</VL>
<PG>A250</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romero-2000" MODIFIED="2009-06-16 12:31:54 +0100" MODIFIED_BY="[Empty name]" NAME="Romero 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-06-16 12:31:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:31:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romero Gomez M, Martinez Delgado C, Grande L, Otero Fernandez MA, Vargas J, Castro Fernandez M</AU>
<TI>Intravenous eradication therapy for bleeding gastroduodenal ulcer associated with Helicobacter pylori infection</TI>
<SO>Revista Española de Enfermedades Digestivas : organo oficial de la Sociedad Española de Patología Digestiva</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>6</NO>
<PG>386-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruiz-Gomez-2002" MODIFIED="2009-07-23 15:29:06 +0100" MODIFIED_BY="[Empty name]" NAME="Ruiz Gomez 2002" YEAR="">
<REFERENCE MODIFIED="2009-07-23 15:29:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz Gomez F, Sanchez Serrano FJ, Martinez Egea A, Garcia Del Castillo G, Sanchez Cuenca J, Coronas Planas M</AU>
<TI>[Inatravenous 3-day Helicobacter pylori eradication therapy is highly effective in patients with bleeding peptic ulcer]</TI>
<SO>Gastroenterología y Hepatología</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>6</NO>
<PG>383-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sepp_x00e4_l_x00e4_-1995" NAME="Seppälä 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Seppälä K, Haapiainen R, Sipponen P, Halttunen J, Färkkilä M, Sarna S, Rautelin H, Finnish Ulcer Bleeding Study Group</AU>
<TI>Two week antimicrobials and omeprazole therapy is sufficient to cure Helicobacter pylori positive bleeding peptic ulcer - A randomized trial</TI>
<SO>Gut</SO>
<YR>1995</YR>
<VL>37 (suppl.2)</VL>
<PG>A193</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheu-1996" MODIFIED="2009-07-23 15:30:44 +0100" MODIFIED_BY="[Empty name]" NAME="Sheu 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-23 15:30:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:30:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheu BS, Yang HB, Su IJ, Shiesh SC, Chi CH, Lin XZ</AU>
<TI>Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1996</YR>
<VL>44</VL>
<NO>6</NO>
<PG>683-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheu-1999" MODIFIED="2009-07-23 15:34:09 +0100" MODIFIED_BY="[Empty name]" NAME="Sheu 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-07-23 15:34:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:34:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheu BS, Chi CH, Yang HB, Jen CM, Lin XZ</AU>
<TI>A three-day course of intravenous omeprazole plus antibiotics for H. pylori-positive bleeding duodenal ulcer</TI>
<SO>Hepatogastroenterology</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>28</NO>
<PG>2363-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheu-2002" MODIFIED="2009-07-23 15:39:08 +0100" MODIFIED_BY="[Empty name]" NAME="Sheu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-23 15:39:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:39:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheu BS, Chi CH, Huang CC, Kao AW, Wang YL, Yang HB</AU>
<TI>Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>1</NO>
<PG>137-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siu-1999" MODIFIED="2009-07-23 15:30:19 +0100" MODIFIED_BY="[Empty name]" NAME="Siu 1999" YEAR="">
<REFERENCE MODIFIED="2009-07-23 15:30:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Siu WT, Luk YW, Kwok ASY, Law BKB, Chau CH, Lao WC et al</AU>
<TI>Ulcer healing drug is not necessary after eradication of Helicobacter pylori in bleeding duodenal ulcer</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>116</VL>
<PG>A313</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sonnenberg-1999" MODIFIED="2009-06-16 12:33:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sonnenberg 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-06-16 12:33:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2009-06-16 12:33:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sonnenberg A, Olson CA, Zhang J</AU>
<TI>The effect of antibiotic therapy on bleeding from duodenal ulcer</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>4</NO>
<PG>950-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Voort-2001" MODIFIED="2009-07-23 15:39:31 +0100" MODIFIED_BY="[Empty name]" NAME="van der Voort 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-23 15:39:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-23 15:39:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Voort PH, van der Hulst RW, Zandstra DF, Geraedts AA, van der Ende A, Tytgat GN</AU>
<TI>Suppression of Helicobacter pylori infection during intensive care stay: related to stress ulcer bleeding incidence?</TI>
<SO>Journal of Critical Care</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>4</NO>
<PG>182-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vergara-2000" MODIFIED="2009-07-23 15:39:59 +0100" MODIFIED_BY="[Empty name]" NAME="Vergara 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-23 15:39:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vergara M, Casellas F, Saperas E, de Torres I, Lopez J, Borruel N et al</AU>
<TI>Helicobacter pylori eradication prevents recurrence from peptic ulcer haemorrhage</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>7</NO>
<PG>733-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20383723"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-07-23 16:43:30 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-07-23 16:43:30 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barthel-1997" MODIFIED="2009-07-23 15:40:39 +0100" MODIFIED_BY="[Empty name]" NAME="Barthel 1997" TYPE="JOURNAL_ARTICLE">
<AU>Barthel JS</AU>
<TI>Bleeding ulcers and Helicobacter pylori</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>4</NO>
<PG>371-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-1996" MODIFIED="2009-07-23 15:43:24 +0100" MODIFIED_BY="[Empty name]" NAME="Bell 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bell GD, Powell KU</AU>
<TI>Helicobacter pylori reinfection after apparent eradication - the Ipswich experience</TI>
<SO>Scandinavian Journal of Gastroenterology. Supplement</SO>
<YR>1996</YR>
<VL>215</VL>
<PG>96-104</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:05:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:05:44 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0085-5928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cutler-1993" MODIFIED="2009-07-23 15:43:54 +0100" MODIFIED_BY="[Empty name]" NAME="Cutler 1993" TYPE="JOURNAL_ARTICLE">
<AU>Cutler AF, Schubert TT</AU>
<TI>Long-term Helicobacter pylori recurrence after successful eradication with triple therapy</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>9</NO>
<PG>1359-61</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:06:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Elta-1994" MODIFIED="2009-05-29 09:07:08 +0100" MODIFIED_BY="[Empty name]" NAME="Elta 1994" TYPE="JOURNAL_ARTICLE">
<AU>Elta GH</AU>
<TI>Helicobacter pylori reinfection: what's the risk?</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>5</NO>
<PG>1563-4</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:07:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:07:03 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0016-5085"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Forbes-1994" MODIFIED="2008-10-30 11:55:24 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Forbes 1994" TYPE="JOURNAL_ARTICLE">
<AU>Forbes GM, Glaser ME, Cullen DJ, Warren JR, Christiansen KJ, Marshall BJ, Collins BJ</AU>
<TI>Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<NO>8892</NO>
<PG>258-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94125737"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garrigan-1999" MODIFIED="2009-07-23 15:44:47 +0100" MODIFIED_BY="[Empty name]" NAME="Garrigan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Garrigan K, McIntosh C, Fraser AG</AU>
<TI>Bleeding peptic ulcers: audit of eradication treatment for H pylori</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1999</YR>
<VL>112</VL>
<NO>1088</NO>
<PG>178-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-1990" MODIFIED="2009-07-23 15:45:06 +0100" MODIFIED_BY="[Empty name]" NAME="Gilbert 1990" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert DA</AU>
<TI>Epidemiology of upper gastrointestinal bleeding</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1990</YR>
<VL>36</VL>
<NO>5 Suppl</NO>
<PG>S8-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91055690"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gisbert-1998" MODIFIED="2009-07-23 15:45:42 +0100" MODIFIED_BY="[Empty name]" NAME="Gisbert 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gisbert JP, Pajares JM, Garcia-Valriberas R, Abraira V, Boixeda D, Garcia-Gravalos R et al</AU>
<TI>Recurrence of Helicobacter pylori infection after eradication: incidence and variables influencing it</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1144-51</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:08:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:07:58 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0036-5521"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gisbert-2002" MODIFIED="2009-07-23 15:46:13 +0100" MODIFIED_BY="[Empty name]" NAME="Gisbert 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gisbert JP, Pajares JM</AU>
<TI>Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>6</NO>
<PG>1047-57</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:08:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:08:41 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0269-2813"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gisbert-2003" MODIFIED="2009-07-23 15:46:34 +0100" MODIFIED_BY="[Empty name]" NAME="Gisbert 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gisbert JP, Pajares JM</AU>
<TI>Helicobacter pylori and bleeding peptic ulcer: what is the prevalence of the infection in patients with this complication?</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>1</NO>
<PG>2-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hawkey-2001" MODIFIED="2009-07-23 15:47:13 +0100" MODIFIED_BY="[Empty name]" NAME="Hawkey 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hawkey CJ, Lanas AI</AU>
<TI>Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement</TI>
<SO>American Journal of Medicine</SO>
<YR>2001</YR>
<VL>110</VL>
<NO>1A</NO>
<PG>79S-100S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-06-02 15:32:18 +0100" MODIFIED_BY="Cathy Bennett" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.</SO>
<YR>2008</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hood-1999" MODIFIED="2009-07-23 15:50:20 +0100" MODIFIED_BY="[Empty name]" NAME="Hood 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hood HM, Wark C, Burgess PA, Nicewander D, Scott MW</AU>
<TI>Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in medicare patients hospitalized with peptic ulcer disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>2</NO>
<PG>149-54</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:09:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:09:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0003-9926"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hopkins-1996" MODIFIED="2008-10-30 11:55:24 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Hopkins 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hopkins RJ, Girardi LS, Turney EA</AU>
<TI>Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>4</NO>
<PG>1244-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96183163"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Howden-1998" MODIFIED="2009-07-23 15:50:53 +0100" MODIFIED_BY="[Empty name]" NAME="Howden 1998" TYPE="JOURNAL_ARTICLE">
<AU>Howden CW, Hunt RH</AU>
<TI>Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>12</NO>
<PG>2330-8</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:10:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:10:38 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0002-9270"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2009-07-23 15:51:15 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96308458"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jaspersen-1995c" MODIFIED="2009-05-29 09:10:56 +0100" MODIFIED_BY="[Empty name]" NAME="Jaspersen 1995c" TYPE="JOURNAL_ARTICLE">
<AU>Jaspersen D</AU>
<TI>Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence?</TI>
<SO>Endoscopy</SO>
<YR>1995</YR>
<VL>27</VL>
<NO>8</NO>
<PG>622-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jensen-1994" MODIFIED="2009-07-23 15:51:50 +0100" MODIFIED_BY="[Empty name]" NAME="Jensen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Jensen DM, Cheng S, Kovacs TO, Randall G, Jensen ME, Reedy T et al</AU>
<TI>A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>6</NO>
<PG>382-6</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:11:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:11:21 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jonsson-1996" MODIFIED="2009-07-23 15:52:22 +0100" MODIFIED_BY="[Empty name]" NAME="Jonsson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jonsson B</AU>
<TI>Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease</TI>
<SO>Scandinavian Journal of Gastroenterology. Supplement</SO>
<YR>1996</YR>
<VL>215</VL>
<PG>90-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuipers-1995" MODIFIED="2009-07-23 15:52:46 +0100" MODIFIED_BY="[Empty name]" NAME="Kuipers 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kuipers EJ, Thijs JC, Festen HP</AU>
<TI>The prevalence of Helicobacter pylori in peptic ulcer disease</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>Suppl 2</NO>
<PG>59-69</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96063803"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lachman-2000" MODIFIED="2009-07-23 15:53:44 +0100" MODIFIED_BY="[Empty name]" NAME="Lachman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lachman L, Howden CW</AU>
<TI>Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>1</NO>
<PG>57-61</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:12:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:12:06 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0002-9270"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laine-1994" MODIFIED="2009-07-23 15:54:25 +0100" MODIFIED_BY="[Empty name]" NAME="Laine 1994" TYPE="JOURNAL_ARTICLE">
<AU>Laine L, Peterson WL</AU>
<TI>Bleeding peptic ulcer</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>11</NO>
<PG>717-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94335929"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laine-1995" MODIFIED="2009-07-23 15:54:41 +0100" MODIFIED_BY="[Empty name]" NAME="Laine 1995" TYPE="OTHER">
<AU>Laine L</AU>
<TI>The long-term management of patients with bleeding ulcers: Helicobacter pylori eradication instead of maintenance antisecretory therapy</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>1</NO>
<PG>77-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laine-1996" MODIFIED="2009-07-23 15:55:14 +0100" MODIFIED_BY="[Empty name]" NAME="Laine 1996" TYPE="JOURNAL_ARTICLE">
<AU>Laine LA</AU>
<TI>Helicobacter pylori and complicated ulcer disease</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1996</YR>
<VL>100</VL>
<NO>5A</NO>
<PG>52S-57S; discussion 57S-59S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McColl-1995" MODIFIED="2009-07-23 15:55:54 +0100" MODIFIED_BY="[Empty name]" NAME="McColl 1995" TYPE="JOURNAL_ARTICLE">
<AU>McColl KE</AU>
<TI>The role of Helicobacter pylori eradication in the management of acute bleeding peptic ulcer</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>8</NO>
<PG>753-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mignon-1994" MODIFIED="2009-07-23 16:43:30 +0100" MODIFIED_BY="[Empty name]" NAME="Mignon 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mignon M, Penston JG, Deltenre M, Ruszniewski P, Dobrill G</AU>
<TI>Natural history of duodenal ulcer disease: Are we at a turning point?</TI>
<SO>Gastroenterology International</SO>
<YR>1994</YR>
<VL>7</VL>
<PG>95-113</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1988" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Murray 1988" TYPE="JOURNAL_ARTICLE">
<AU>Murray WR, Cooper G, Laferla G, Rogers P, Archibald M</AU>
<TI>Maintenance ranitidine treatment after haemorrhage from a duodenal ulcer. A 3-year study</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1988</YR>
<VL>23</VL>
<NO>2</NO>
<PG>183-7</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:13:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:13:44 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0036-5521"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NIH-1994" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="NIH 1994" TYPE="JOURNAL_ARTICLE">
<AU>NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease [see comments]</AU>
<TI>NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<NO>1</NO>
<PG>65-9</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:01:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:01:37 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="94275963"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ofman-2002" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Ofman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ofman J, Wallace J, Badamgarav E, Chiou CF, Henning J, Laine L</AU>
<TI>The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>8</NO>
<PG>1941-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Penston-1992" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Penston 1992" TYPE="JOURNAL_ARTICLE">
<AU>Penston JG, Wormsley KG</AU>
<TI>Review article: maintenance treatment with H2-receptor antagonists for peptic ulcer disease</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>1</NO>
<PG>3-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petersen-1995" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Petersen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Petersen H, Kristensen P, Johannessen T, Kleveland PM, Dybdahl JH, Myrvold H</AU>
<TI>The natural course of peptic ulcer disease and its predictors</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1995</YR>
<VL>30</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:14:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:14:26 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0036-5521"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sharma-2001" MODIFIED="2009-05-29 09:14:38 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sharma VK, Sahai AV, Corder FA, Howden CW</AU>
<TI>Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>12</NO>
<PG>1939-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soll-1996" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Soll 1996" TYPE="JOURNAL_ARTICLE">
<AU>Soll AH</AU>
<TI>Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<NO>8</NO>
<PG>622-9</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:15:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-29 09:15:03 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0098-7484"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sonnenberg-1999" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sonnenberg 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sonnenberg A, Pauly MP, Levenson SD, Schwartz JS</AU>
<TI>Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer (Clinical Trial)</TI>
<SO>American Journal of Managed Care</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>1</NO>
<PG>53-9</PG>
<IDENTIFIERS MODIFIED="2009-05-29 09:15:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-van-Leerdam-2002" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="van Leerdam 2002" TYPE="JOURNAL_ARTICLE">
<AU>van Leerdam ME, Tytgat GN</AU>
<TI>Review article: Helicobacter pylori infection in peptic ulcer haemorrhage</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>16 Suppl 1</VL>
<PG>66-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-1997" MODIFIED="2009-07-23 16:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 1997" TYPE="JOURNAL_ARTICLE">
<AU>Xia HX, Talley NJ, Keane CT, O'Morain CA</AU>
<TI>Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>9</NO>
<PG>1821-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97470683"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-23 13:36:57 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-07-23 13:36:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Arkkila-2003">
<CHAR_METHODS>
<P>Randomized<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal and gastric ulcer<BR/>Some patients used NSAIDs (19%) or ASA (35%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OBAM/OA vs. O<BR/>No maintenance antisecretory therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Follow-up 12 months in all patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=3<BR/>Eradication rates: 92% in eradication groups, and 4% in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-06-02 15:33:34 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Bataga-1997">
<CHAR_METHODS>
<P>Randomized<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal ulcer<BR/>NSAID use unknown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-02 15:33:34 +0100" MODIFIED_BY="Cathy Bennett">
<P>BAM (with or without endoscopic haemostasis) vs. H2-antagonist<BR/>No maintenance antisecretory therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Follow-up 12 months in all patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=1<BR/>Eradication rates not provided in any group<BR/>Abstract form only (no complete article)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Graham-1993">
<CHAR_METHODS>
<P>Randomized<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal and gastric ulcer<BR/>Some patients (28%) used NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BMT vs. ranitidine<BR/>No maintenance antisecretory therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Mean follow-up 12 months in eradication group, and 9 months in antisecretory group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=2<BR/>Eradication rates: 81% in eradication group, and 0% in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-29 12:27:27 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Jaspersen-1995a">
<CHAR_METHODS>
<P>Randomized<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-29 12:27:27 +0000" MODIFIED_BY="Cathy Bennett">
<P>Duodenal ulcer. No patient used NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OA vs. O<BR/>No maintenance antisecretory therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Follow-up 12 months in all patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=2<BR/>Eradication rates: 83% in eradication group, and 5% in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lai-2000">
<CHAR_METHODS>
<P>Randomized<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal ulcer<BR/>No patient used NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BAM vs. B<BR/>No maintenance antisecretory therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Mean follow-up 53 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=3<BR/>Eradication rates: 85% in eradication group, and 2% in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Riemann-1997">
<CHAR_METHODS>
<P>Randomized<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal and gastric ulcer<BR/>No patient used NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OA vs. ranitidine (as maintenance antisecretory therapy)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Mean follow-up 19 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=2<BR/>Eradication rates: 89% in eradication group, and not provided in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rokkas-1995">
<CHAR_METHODS>
<P>Randomized<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal ulcer<BR/>Some patients (6%) used NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OA vs. O<BR/>No maintenance antisecretory therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Follow-up 12 months in all patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=3<BR/>Eradication rates: 81% in eradication group, and 13% in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-06-02 15:33:34 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Santander-1996">
<CHAR_METHODS MODIFIED="2009-06-02 15:33:34 +0100" MODIFIED_BY="Cathy Bennett">
<P>Not randomised<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal and gastric ulcer<BR/>No patient used NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OA/OC/BAM vs. ranitidine/O (as maintenance antisecretory therapy)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Follow-up 12 months in all patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=1<BR/>Eradication rates: 100% in eradication group (retreatment was prescribed in failures), and not provided in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sung-1997">
<CHAR_METHODS>
<P>Randomized<BR/>Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal and gastric ulcer<BR/>No patient used NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BAM vs. ranitidine (as maintenance antisecretory therapy)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Median follow-up 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=2<BR/>Eradication rates: 98% in eradication group, and 6% in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-06-26 12:04:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vcev-1996">
<CHAR_METHODS MODIFIED="2009-06-26 12:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized Not double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Duodenal ulcer<BR/>NSAID use unknown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OA vs. O<BR/>No maintenance antisecretory therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rebleeding<BR/>Follow-up 12 months in all patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Q=1<BR/>Eradication rates: 72% in eradication group, and 0% in antisecretory group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Intervention (treatment): B: bismuth; A: amoxicillin; M: metronidazole; O: omeprazole; C: clarithromycin; T: tetracycline; details of eradication and antisecretory treatment are provided in additional table (01).<BR/>NSAIDs: non-steroidal anti-inflammatory drugs (taken by the patient previous to the inclusion in the study).<BR/>ASA: acetylsalicylic acid (taken by the patient previous to the inclusion in the study).<BR/>Q: quality score (Jadad scale, from 0 to 5 points, see appropriate section).<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-01 12:00:13 +0100" MODIFIED_BY="Cathy Bennett" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adamek-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Altorjay-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated<BR/>Less than six-month follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:57:50 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Amendola-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:57:50 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arkkila-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data (no response from the authors)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:57:58 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Capurso-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:57:58 +0100" MODIFIED_BY="Cathy Bennett">
<P>No previous upper gastrointestinal bleeding<BR/>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>All patients received NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>All patients received NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-2002a">
<CHAR_REASON_FOR_EXCLUSION>
<P>All patients received NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>All patients received NSAIDs<BR/>No previous upper gastrointestinal bleeding in one group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:00 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Chen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:00 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)<BR/>Less than six-month follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:02 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Chen-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:02 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)<BR/>Less than six-months follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:09 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Di-Mario-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:09 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:12 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Fakhreih-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:12 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:15 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Gisbert-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:15 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients -one- received <I>H. pylori</I> eradication therapy)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:19 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Gisbert-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:19 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hsieh-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:21 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Huellin-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:21 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:23 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Jaspersen-1994a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:23 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:25 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Jaspersen-1994b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:25 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)<BR/>Less than six-month follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:28 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Jaspersen-1995b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:30 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Krizman-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:30 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:32 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Kung-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:32 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)<BR/>Less than six-month follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:58:34 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Labenz-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:58:34 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:59:38 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Lai-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:59:38 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori </I>eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lai-2000b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:59:42 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Lee-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:59:42 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:59:45 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Lin-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:59:45 +0100" MODIFIED_BY="Cathy Bennett">
<P>No <I>H. pylori</I> eradication group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:59:47 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Loperfido-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:59:47 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:59:49 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Macri-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:59:49 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:59:51 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Martino-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:59:51 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)<BR/>No previous upper gastrointestinal bleeding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:59:55 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Pamos-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:59:55 +0100" MODIFIED_BY="Cathy Bennett">
<P>Control group included only <I>H. pylori</I>-negative patients or patients with unknown <I>H. pylori</I> status</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 11:59:57 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Pauly-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 11:59:57 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all <I>H. pylori</I>-positive patients received eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 12:00:00 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Pazzi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 12:00:00 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 12:00:02 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Pazzi-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 12:00:02 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 12:00:04 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Pellicano-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 12:00:04 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 12:00:07 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Pica-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 12:00:07 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romero-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruiz-Gomez-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sepp_x00e4_l_x00e4_-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data (no response from the authors)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sheu-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sheu-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rebleeding not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 12:00:09 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Sheu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 12:00:09 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)<BR/>Less than six-month follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 12:00:11 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Siu-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 12:00:11 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sonnenberg-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No previous upper gastrointestinal bleeding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Voort-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Stress ulcer bleeding<BR/>No previous upper gastrointestinal bleeding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-01 12:00:13 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Vergara-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-01 12:00:13 +0100" MODIFIED_BY="Cathy Bennett">
<P>No control group (all patients received <I>H. pylori</I> eradication therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>NSAIDs: non-steroidal anti-inflammatory drugs<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-07-23 13:36:57 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-07-23 13:36:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-26 11:16:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arkkila-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bataga-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-26 11:54:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graham-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-26 11:55:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaspersen-1995a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 11:36:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lai-2000">
<DESCRIPTION>
<P>Quote: "Consecutive patients were randomized and the treatment was determined by a list of random numbers generated by computer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-26 11:56:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riemann-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 13:36:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rokkas-1995">
<DESCRIPTION>
<P>Quote: "Random allocation of patients was achieved by opening scaled envelopes according to a computer-generated program of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-26 11:36:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Santander-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sung-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vcev-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Arkkila-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bataga-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Graham-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jaspersen-1995a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lai-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Riemann-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rokkas-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Santander-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sung-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vcev-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-06-26 12:04:22 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 11:52:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arkkila-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 11:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bataga-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 11:25:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Graham-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 11:31:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaspersen-1995a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 11:31:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lai-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 11:32:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riemann-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 11:34:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rokkas-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 11:36:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Santander-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 12:02:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sung-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-26 12:04:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vcev-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-06-02 14:17:06 +0100" MODIFIED_BY="Cathy Bennett" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-07-01 12:00:31 +0100" MODIFIED_BY="Cathy Bennett">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-06-02 15:34:14 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE>Details of eradication and antisecretory treatment of included studies</TITLE>
<TABLE COLS="3" ROWS="12">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Eradication treatment</P>
</TH>
<TH>
<P>Antisecretory treatment</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Arkkila-2003" TYPE="STUDY">Arkkila 2003</LINK>
</P>
</TD>
<TD>
<P>Bismuth subcitrate, 120 q.i.d., for 14 days, amoxicillin, 500 mg q.i.d., metronidazole, 400 mg t.i.d., and omeprazole, 40 mg o.d., for 28 days; amoxicillin, 500 mg q.i.d., for 14 days, and omeprazole, 40 mg o.d., for 28 days</P>
</TD>
<TD>
<P>Omeprazole, 40 mg o.d., for 28 days plus placebo q.i.d., for 14 days</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bataga-1997" TYPE="STUDY">Bataga 1997</LINK>
</P>
</TD>
<TD>
<P>H2-antagonist (dose not stated) for 7 days, followed by bismuth subcitrate, 240 mg b.i.d., metronidazole, 500 mg t.i.d., and amoxicillin 500 mg t.i.d., for 10 days (with and without endoscopic haemostasis with pure ethanol)</P>
</TD>
<TD>
<P>H2-antagonist (dose not stated) and antiacids for 7 days</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Graham-1993" TYPE="STUDY">Graham 1993</LINK>
</P>
</TD>
<TD>
<P>Bismuth subsalicylate 5-8 tablets daily, metronidazole, 250 mg t.i.d., and tetracycline, 500 mg q.i.d., for 14 days, and ranitidine, 300 mg o.d., until ulcer healing</P>
</TD>
<TD>
<P>Ranitidine, 300 mg o.d., until ulcer healing</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jaspersen-1995a" TYPE="STUDY">Jaspersen 1995a</LINK>
</P>
</TD>
<TD>
<P>Omeprazole, 40 mg o.d. and amoxicillin, 1 g b.i.d., for 14 days</P>
</TD>
<TD>
<P>Omeprazole, 40 mg o.d., for 14 days</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>
</P>
</TD>
<TD>
<P>Metronidazole, 300 mg q.i.d., and amoxicillin, 500 mg q.i.d., for 14 days, and tripotassium dicitrato bismuthate, 120 mg q.i.d., until ulcer healing</P>
</TD>
<TD>
<P>Tripotassium dicitrato bismuthate, 120 mg q.i.d., until ulcer healing</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Riemann-1997" TYPE="STUDY">Riemann 1997</LINK>
</P>
</TD>
<TD>
<P>Omeprazole, 60 mg b.i.d, and amoxicillin, 750 mg t.i.d., for 10 days, followed by omeprazole, 20 mg o.d., for 30 days</P>
</TD>
<TD>
<P>Ranitidine, 300 mg o.d., for 6 weeks, followed by antisecretory maintenance therapy with ranitidine, 150 mg o.d.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rokkas-1995" TYPE="STUDY">Rokkas 1995</LINK>
</P>
</TD>
<TD>
<P>Omeprazole, 20 mg o.d. for 30 days, followed by omeprazole, 20 mg t.i.d., and amoxicillin, 500 mg q.i.d., for 14 days</P>
</TD>
<TD>
<P>Omeprazole, 20 mg o.d., for 30 days, followed by omeprazole, 20 mg t.i.d., for 14 days</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Santander-1996" TYPE="STUDY">Santander 1996</LINK>
</P>
</TD>
<TD>
<P>Omeprazole, 20 mg b.i.d., and clarithromycin, 500 mg t.i.d., for 12 days; or omeprazole, 20 mg b.i.d., and amoxicillin, 500 mg t.i.d., for 10 days; or bismuth subsalicylate, 240 mg b.i.d., for 30 days, metronidazole, 500 mg t.i.d., for 10 days, and amoxicillin, 500 mg t.i.d., for 10 days</P>
</TD>
<TD>
<P>Antisecretory maintenance therapy with ranitidine, 150 mg o.d., or omeprazole, 20 mg o.d.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sung-1997" TYPE="STUDY">Sung 1997</LINK>
</P>
</TD>
<TD>
<P>Bismuth subsalicylate, 120 mg q.i.d., metronidazole, 400 mg q.i.d., tetracycline, 500 mg q.i.d., and ranitidine, 300 mg o.d., for 7 days</P>
</TD>
<TD>
<P>Ranitidine, 300 mg o.d., for 6 weeks, followed by antisecretory maintenance therapy with ranitidine, 150 mg o.d.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vcev-1996" TYPE="STUDY">Vcev 1996</LINK>
</P>
</TD>
<TD>
<P>Omeprazole, 20 or 40 mg o.d, and amoxicillin, 500 mg q.i.d. or 1 g b.i.d., for 14 days, followed by omeprazole, 20 mg o.d., for 14 days</P>
</TD>
<TD>
<P>Omeprazole, 20 mg o.d., for 30 days</P>
</TD>
</TR>
<TR>
<TD>
<P>Footnotes:</P>
</TD>
<TD>
<P>o.d.: once per day; b.i.d.: two times per day; t.i.d.: three times per day; q.i.d.: four times per day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-07-01 12:00:31 +0100" MODIFIED_BY="Cathy Bennett" NO="2">
<TITLE MODIFIED="2009-06-02 15:34:41 +0100" MODIFIED_BY="Cathy Bennett">Rebleeding in H. pylori eradicated patients and no maintenance antisecretory treatment</TITLE>
<TABLE COLS="7" ROWS="31">
<TR>
<TH>
<P>Author &amp; year</P>
</TH>
<TH>
<P>N. of patients</P>
</TH>
<TH>
<P>Mean follow-up (mo.)</P>
</TH>
<TH>
<P>Rebleeding (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
<TH>
<P>Follow-up (p-y)</P>
</TH>
<TH>
<P>Yearly rebleeding (%</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Arkkila-2003" TYPE="STUDY">Arkkila 2003</LINK>
</P>
</TD>
<TD>
<P>176</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>2 (1.1%)</P>
</TD>
<TD>
<P>The two patients had Dieulafoy's ulcer</P>
</TD>
<TD>
<P>176</P>
</TD>
<TD>
<P>1.1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bataga-1997" TYPE="STUDY">Bataga 1997</LINK>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Graham-1993" TYPE="STUDY">Graham 1993</LINK>
</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jaspersen-1995a" TYPE="STUDY">Jaspersen 1995a</LINK>
</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lai-2000" TYPE="STUDY">Lai 2000</LINK>
</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>2 (4.9%)</P>
</TD>
<TD>
<P>One of these patients took NSAIDs at the time of rebleeding; another patient had recurrence of <I>H. pylori</I> infection at the time of rebleeding</P>
</TD>
<TD>
<P>177</P>
</TD>
<TD>
<P>3.4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Riemann-1997" TYPE="STUDY">Riemann 1997</LINK>
</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>2 (4.8%)</P>
</TD>
<TD>
<P>The two patients took NSAIDs at the time of rebleeding (and were <I>H. pylori</I>-negative)</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rokkas-1995" TYPE="STUDY">Rokkas 1995</LINK>
</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Santander-1996" TYPE="STUDY">Santander 1996</LINK>
</P>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>2 (2.4%)</P>
</TD>
<TD>
<P>The two patients had recurrence of <I>H. pylori</I> infection at the time of rebleeding</P>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>2.4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sung-1997" TYPE="STUDY">Sung 1997</LINK>
</P>
</TD>
<TD>
<P>108</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>108</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vcev-1996" TYPE="STUDY">Vcev 1996</LINK>
</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Studies not included in the meta-analysis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Amendola-1999" TYPE="STUDY">Amendola 1999</LINK>
</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Di-Mario-1997" TYPE="STUDY">Di Mario 1997</LINK>
</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fakhreih-1995" TYPE="STUDY">Fakhreih 1995</LINK>
</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>3 (4.9%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>4.9</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gisbert-1999" TYPE="STUDY">Gisbert 1999</LINK>
</P>
</TD>
<TD>
<P>111</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>111</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Huellin-1998" TYPE="STUDY">Huellin 1998</LINK>
</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>1 (1.2%)</P>
</TD>
<TD>
<P>This patient took NSAIDs at the time of rebleeding</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>0.8</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jaspersen-1995b" TYPE="STUDY">Jaspersen 1995b</LINK>
</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>1 (3.4%)</P>
</TD>
<TD>
<P>This patient had recurrence of <I>H. pylori</I> infection at the time of rebleeding</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>3.4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Krizman-1997" TYPE="STUDY">Krizman 1997</LINK>
</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Labenz-1994" TYPE="STUDY">Labenz 1994</LINK>
</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lai-1998" TYPE="STUDY">Lai 1998</LINK>
</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lee-1999" TYPE="STUDY">Lee 1999</LINK>
</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Loperfido-2001" TYPE="STUDY">Loperfido 2001</LINK>
</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Macri-1998" TYPE="STUDY">Macri 1998</LINK>
</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pamos-1998" TYPE="STUDY">Pamos 1998</LINK>
</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pazzi-1999" TYPE="STUDY">Pazzi 1999</LINK>
</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>4 (10.3%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>153</P>
</TD>
<TD>
<P>2.6</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pellicano-2001" TYPE="STUDY">Pellicano 2001</LINK>
</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>180</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pica-1996" TYPE="STUDY">Pica 1996</LINK>
</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vergara-2000" TYPE="STUDY">Vergara 2000</LINK>
</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>0 (0%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>209</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Total</P>
</TD>
<TD>
<P>1370</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17 (1.24%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2179</P>
</TD>
<TD>
<P>0.78</P>
</TD>
</TR>
<TR>
<TD>
<P>Footnotes:</P>
</TD>
<TD>
<P>p-y: patient-years</P>
</TD>
<TD>
<P>NSAIDs: non-steroidal anti-inflammatory drugs</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-06-29 11:54:22 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-06-29 11:47:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Eradication vs non-eradication therapy (without long-term maintenance antisecretory therapy)</NAME>
<DICH_OUTCOME CHI2="6.144053591095998" CI_END="0.31921476600594073" CI_START="0.09590147183584599" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.17496618499500094" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="40" I2="2.3446018001008606" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.49591702757638867" LOG_CI_START="-1.0181747274979385" LOG_EFFECT_SIZE="-0.7570458775371636" METHOD="PETO" MODIFIED="2009-06-26 09:51:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4072484212548555" P_Q="1.0" P_Z="1.3298403971099213E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="375" TOTAL_2="203" WEIGHT="100.0" Z="5.682185843656283">
<NAME>Recurrent bleeding</NAME>
<GROUP_LABEL_1>Eradication tx.</GROUP_LABEL_1>
<GROUP_LABEL_2>No eradication tx.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours eradication</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antisecretor</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8072121535594745" CI_START="0.010549433588946314" EFFECT_SIZE="0.09228017666956438" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="-0.09301230789096747" LOG_CI_START="-1.9767708575036067" LOG_EFFECT_SIZE="-1.0348915826972869" ORDER="1133" O_E="-1.9461883408071747" SE="1.1065290967976724" STUDY_ID="STD-Arkkila-2003" TOTAL_1="176" TOTAL_2="47" VAR="0.8167221294370443" WEIGHT="7.686333617355072"/>
<DICH_DATA CI_END="0.8898675883243541" CI_START="0.008254855063793701" EFFECT_SIZE="0.08570722237702716" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="-0.05067461126324611" LOG_CI_START="-2.083290547543187" LOG_EFFECT_SIZE="-1.0669825794032164" ORDER="1127" O_E="-1.7234042553191489" SE="1.1939686625819934" STUDY_ID="STD-Bataga-1997" TOTAL_1="27" TOTAL_2="20" VAR="0.7014781427756017" WEIGHT="6.601749648160509"/>
<DICH_DATA CI_END="0.6807287840548166" CI_START="0.01071571838855346" EFFECT_SIZE="0.08540783306532156" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.16702588522340533" LOG_CI_START="-1.9699787082687863" LOG_EFFECT_SIZE="-1.0685022967460958" ORDER="1128" O_E="-2.193548387096774" SE="1.0590634130172676" STUDY_ID="STD-Graham-1993" TOTAL_1="17" TOTAL_2="14" VAR="0.8915712799167533" WEIGHT="8.39075378772466"/>
<DICH_DATA CI_END="0.4177919520022647" CI_START="0.01386006689614692" EFFECT_SIZE="0.07609615235623408" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.37903993016392207" LOG_CI_START="-1.8582346735801027" LOG_EFFECT_SIZE="-1.1186373018720124" ORDER="1129" O_E="-3.411764705882353" SE="0.8688863144147343" STUDY_ID="STD-Jaspersen-1995a" TOTAL_1="29" TOTAL_2="22" VAR="1.3245674740484428" WEIGHT="12.465766675443597"/>
<DICH_DATA CI_END="1.24630981283573" CI_START="0.16935763934236997" EFFECT_SIZE="0.4594258240359266" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.09562601445805988" LOG_CI_START="-0.7711952085297851" LOG_EFFECT_SIZE="-0.33778459703586255" ORDER="1130" O_E="-3.0" SE="0.5091750772173156" STUDY_ID="STD-Lai-2000" TOTAL_1="60" TOTAL_2="60" VAR="3.8571428571428568" WEIGHT="36.30033488897089"/>
<DICH_DATA CI_END="0.606189650800073" CI_START="0.014000413942628994" EFFECT_SIZE="0.09212440522976928" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.21739148241707237" LOG_CI_START="-1.8538591235830517" LOG_EFFECT_SIZE="-1.035625303000062" ORDER="1131" O_E="-2.5806451612903225" SE="0.9612691930663656" STUDY_ID="STD-Rokkas-1995" TOTAL_1="16" TOTAL_2="15" VAR="1.0822060353798126" WEIGHT="10.184855204521064"/>
<DICH_DATA CI_END="0.621509469412021" CI_START="0.03757865991501376" EFFECT_SIZE="0.15282504043838815" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="-0.20655224999569444" LOG_CI_START="-1.425058711246984" LOG_EFFECT_SIZE="-0.8158054806213393" ORDER="1132" O_E="-3.666666666666667" SE="0.7157567270432688" STUDY_ID="STD-Vcev-1996" TOTAL_1="50" TOTAL_2="25" VAR="1.951951951951952" WEIGHT="18.37020617782422"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.904778932767188" CI_END="0.2986952883223303" CI_START="0.08879682889876044" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.16285943144326606" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.5247716279876072" LOG_CI_START="-1.0516025434146496" LOG_EFFECT_SIZE="-0.7881870857011284" METHOD="PETO" MODIFIED="2009-06-29 11:43:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5560828454306872" P_Q="1.0" P_Z="4.502990269266467E-9" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="374" TOTAL_2="203" WEIGHT="99.99999999999997" Z="5.8645696591347045">
<NAME>Recurrent bleeding excluding NSAID users</NAME>
<GROUP_LABEL_1>Eradication tx.</GROUP_LABEL_1>
<GROUP_LABEL_2>No eradication tx.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours eradication</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antisecretor</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8072121535594745" CI_START="0.010549433588946314" EFFECT_SIZE="0.09228017666956438" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="-0.09301230789096747" LOG_CI_START="-1.9767708575036067" LOG_EFFECT_SIZE="-1.0348915826972869" ORDER="1140" O_E="-1.9461883408071747" SE="1.1065290967976724" STUDY_ID="STD-Arkkila-2003" TOTAL_1="176" TOTAL_2="47" VAR="0.8167221294370443" WEIGHT="7.821535695978914"/>
<DICH_DATA CI_END="0.8898675883243541" CI_START="0.008254855063793701" EFFECT_SIZE="0.08570722237702716" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="-0.05067461126324611" LOG_CI_START="-2.083290547543187" LOG_EFFECT_SIZE="-1.0669825794032164" ORDER="1134" O_E="-1.7234042553191489" SE="1.1939686625819934" STUDY_ID="STD-Bataga-1997" TOTAL_1="27" TOTAL_2="20" VAR="0.7014781427756017" WEIGHT="6.7178739695105705"/>
<DICH_DATA CI_END="0.6807287840548166" CI_START="0.01071571838855346" EFFECT_SIZE="0.08540783306532156" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.16702588522340533" LOG_CI_START="-1.9699787082687863" LOG_EFFECT_SIZE="-1.0685022967460958" ORDER="1135" O_E="-2.193548387096774" SE="1.0590634130172676" STUDY_ID="STD-Graham-1993" TOTAL_1="17" TOTAL_2="14" VAR="0.8915712799167533" WEIGHT="8.538346568600028"/>
<DICH_DATA CI_END="0.4177919520022647" CI_START="0.01386006689614692" EFFECT_SIZE="0.07609615235623408" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.37903993016392207" LOG_CI_START="-1.8582346735801027" LOG_EFFECT_SIZE="-1.1186373018720124" ORDER="1136" O_E="-3.411764705882353" SE="0.8688863144147343" STUDY_ID="STD-Jaspersen-1995a" TOTAL_1="29" TOTAL_2="22" VAR="1.3245674740484428" WEIGHT="12.685038652183497"/>
<DICH_DATA CI_END="1.0933827133302148" CI_START="0.14143104940653314" EFFECT_SIZE="0.3932407208685983" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.03877220329923167" LOG_CI_START="-0.8494552361853016" LOG_EFFECT_SIZE="-0.405341516443035" ORDER="1137" O_E="-3.428571428571429" SE="0.521749194749951" STUDY_ID="STD-Lai-2000" TOTAL_1="59" TOTAL_2="60" VAR="3.6734693877551026" WEIGHT="35.1798621695448"/>
<DICH_DATA CI_END="0.606189650800073" CI_START="0.014000413942628994" EFFECT_SIZE="0.09212440522976928" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.21739148241707237" LOG_CI_START="-1.8538591235830517" LOG_EFFECT_SIZE="-1.035625303000062" ORDER="1138" O_E="-2.5806451612903225" SE="0.9612691930663656" STUDY_ID="STD-Rokkas-1995" TOTAL_1="16" TOTAL_2="15" VAR="1.0822060353798126" WEIGHT="10.364006105676971"/>
<DICH_DATA CI_END="0.621509469412021" CI_START="0.03757865991501376" EFFECT_SIZE="0.15282504043838815" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="-0.20655224999569444" LOG_CI_START="-1.425058711246984" LOG_EFFECT_SIZE="-0.8158054806213393" ORDER="1139" O_E="-3.666666666666667" SE="0.7157567270432688" STUDY_ID="STD-Vcev-1996" TOTAL_1="50" TOTAL_2="25" VAR="1.951951951951952" WEIGHT="18.6933368385052"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2954909678153" CI_END="0.1948055131874011" CI_START="0.05404500637514711" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.10260733503081979" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.710398756322986" LOG_CI_START="-1.2672444275923849" LOG_EFFECT_SIZE="-0.9888215919576855" METHOD="PETO" MODIFIED="2009-06-29 11:44:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7709494712686844" P_Q="1.0" P_Z="3.382679080930877E-12" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="203" WEIGHT="100.0" Z="6.960832443770599">
<NAME>Recurrent bleeding excluding H. pylori eradication failures</NAME>
<GROUP_LABEL_1>Eradication tx.</GROUP_LABEL_1>
<GROUP_LABEL_2>No eradication tx.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours eradication</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antisecretor</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8072121535594745" CI_START="0.010549433588946314" EFFECT_SIZE="0.09228017666956438" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="-0.09301230789096747" LOG_CI_START="-1.9767708575036067" LOG_EFFECT_SIZE="-1.0348915826972869" ORDER="1147" O_E="-1.9461883408071747" SE="1.1065290967976724" STUDY_ID="STD-Arkkila-2003" TOTAL_1="176" TOTAL_2="47" VAR="0.8167221294370443" WEIGHT="8.738144517091618"/>
<DICH_DATA CI_END="0.8898675883243541" CI_START="0.008254855063793701" EFFECT_SIZE="0.08570722237702716" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="-0.05067461126324611" LOG_CI_START="-2.083290547543187" LOG_EFFECT_SIZE="-1.0669825794032164" ORDER="1141" O_E="-1.7234042553191489" SE="1.1939686625819934" STUDY_ID="STD-Bataga-1997" TOTAL_1="27" TOTAL_2="20" VAR="0.7014781427756017" WEIGHT="7.505144242117327"/>
<DICH_DATA CI_END="0.6807287840548166" CI_START="0.01071571838855346" EFFECT_SIZE="0.08540783306532156" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.16702588522340533" LOG_CI_START="-1.9699787082687863" LOG_EFFECT_SIZE="-1.0685022967460958" ORDER="1142" O_E="-2.193548387096774" SE="1.0590634130172676" STUDY_ID="STD-Graham-1993" TOTAL_1="17" TOTAL_2="14" VAR="0.8915712799167533" WEIGHT="9.538958735660739"/>
<DICH_DATA CI_END="0.4177919520022647" CI_START="0.01386006689614692" EFFECT_SIZE="0.07609615235623408" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.37903993016392207" LOG_CI_START="-1.8582346735801027" LOG_EFFECT_SIZE="-1.1186373018720124" ORDER="1143" O_E="-3.411764705882353" SE="0.8688863144147343" STUDY_ID="STD-Jaspersen-1995a" TOTAL_1="29" TOTAL_2="22" VAR="1.3245674740484428" WEIGHT="14.171603283055742"/>
<DICH_DATA CI_END="0.6559655469754" CI_START="0.07080817917838049" EFFECT_SIZE="0.2155173449750124" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.18311897030635707" LOG_CI_START="-1.1499165732866377" LOG_EFFECT_SIZE="-0.6665177717964973" ORDER="1144" O_E="-4.758620689655173" SE="0.5679016977159347" STUDY_ID="STD-Lai-2000" TOTAL_1="56" TOTAL_2="60" VAR="3.1006565682675897" WEIGHT="33.17405542821164"/>
<DICH_DATA CI_END="0.606189650800073" CI_START="0.014000413942628994" EFFECT_SIZE="0.09212440522976928" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.21739148241707237" LOG_CI_START="-1.8538591235830517" LOG_EFFECT_SIZE="-1.035625303000062" ORDER="1145" O_E="-2.5806451612903225" SE="0.9612691930663656" STUDY_ID="STD-Rokkas-1995" TOTAL_1="16" TOTAL_2="15" VAR="1.0822060353798126" WEIGHT="11.578568026478955"/>
<DICH_DATA CI_END="0.19683792967844974" CI_START="0.007416580449608914" EFFECT_SIZE="0.038208171128630126" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="-0.7058912114796226" LOG_CI_START="-2.1297962880063164" LOG_EFFECT_SIZE="-1.4178437497429695" ORDER="1146" O_E="-4.666666666666667" SE="0.8364088903955846" STUDY_ID="STD-Vcev-1996" TOTAL_1="50" TOTAL_2="25" VAR="1.4294294294294292" WEIGHT="15.293525767383999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2824596313307914" CI_END="0.6121955291116626" CI_START="0.11948502720648771" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2704592380592631" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" I2="39.07008083480528" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.2131098463970053" LOG_CI_START="-0.9226865132012656" LOG_EFFECT_SIZE="-0.5678981797991355" METHOD="PETO" MODIFIED="2009-06-29 11:47:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.19374180579485978" P_Q="1.0" P_Z="0.001705401840188656" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="252" TOTAL_2="122" WEIGHT="99.99999999999999" Z="3.1372507901227253">
<NAME>Recurrent bleeding considering high quality studies</NAME>
<GROUP_LABEL_1>Eradication tx.</GROUP_LABEL_1>
<GROUP_LABEL_2>No eradication tx.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours eradication</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antisecretor</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8072121535594745" CI_START="0.010549433588946314" EFFECT_SIZE="0.09228017666956438" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="-0.09301230789096747" LOG_CI_START="-1.9767708575036067" LOG_EFFECT_SIZE="-1.0348915826972869" ORDER="1148" O_E="-1.9461883408071747" SE="1.1065290967976724" STUDY_ID="STD-Arkkila-2003" TOTAL_1="176" TOTAL_2="47" VAR="0.8167221294370443" WEIGHT="14.188882074616632"/>
<DICH_DATA CI_END="1.24630981283573" CI_START="0.16935763934236997" EFFECT_SIZE="0.4594258240359266" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.09562601445805988" LOG_CI_START="-0.7711952085297851" LOG_EFFECT_SIZE="-0.33778459703586255" ORDER="1149" O_E="-3.0" SE="0.5091750772173156" STUDY_ID="STD-Lai-2000" TOTAL_1="60" TOTAL_2="60" VAR="3.8571428571428568" WEIGHT="67.0099941857502"/>
<DICH_DATA CI_END="0.606189650800073" CI_START="0.014000413942628994" EFFECT_SIZE="0.09212440522976928" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.21739148241707237" LOG_CI_START="-1.8538591235830517" LOG_EFFECT_SIZE="-1.035625303000062" ORDER="1150" O_E="-2.5806451612903225" SE="0.9612691930663656" STUDY_ID="STD-Rokkas-1995" TOTAL_1="16" TOTAL_2="15" VAR="1.0822060353798126" WEIGHT="18.801123739633155"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-06-29 11:54:22 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Eradication therapy vs. long-term maintenance antisecretory therapy</NAME>
<DICH_OUTCOME CHI2="1.3133896260557214" CI_END="0.6710325236071994" CI_START="0.08580035330042968" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.23994755177241678" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.1732564299340902" LOG_CI_START="-1.0665109238516306" LOG_EFFECT_SIZE="-0.6198836768928605" METHOD="PETO" MODIFIED="2009-06-29 11:51:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5185624857344517" P_Q="1.0" P_Z="0.006522731527945291" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="257" TOTAL_2="213" WEIGHT="100.0" Z="2.7202766727450167">
<NAME>Recurrent bleeding</NAME>
<GROUP_LABEL_1>Eradication tx.</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance antisec.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours eradication</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antisecretor</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6189490315267916" CI_START="0.09761801680691726" EFFECT_SIZE="0.5056249702853312" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41812704651913957" LOG_CI_START="-1.0104700196518521" LOG_EFFECT_SIZE="-0.2961714865663562" ORDER="1151" O_E="-0.9684210526315788" SE="0.8391649883383684" STUDY_ID="STD-Riemann-1997" TOTAL_1="47" TOTAL_2="48" VAR="1.4200554016620497" WEIGHT="39.095872687638625"/>
<DICH_DATA CI_END="0.7992107630021884" CI_START="0.03145638189011003" EFFECT_SIZE="0.15855686352751514" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.09733867608214365" LOG_CI_START="-1.5022912313479353" LOG_EFFECT_SIZE="-0.7998149537150395" ORDER="1152" O_E="-2.7039999999999997" SE="0.8252760855904374" STUDY_ID="STD-Santander-1996" TOTAL_1="84" TOTAL_2="41" VAR="1.4682549677419354" WEIGHT="40.422866054836206"/>
<DICH_DATA CI_END="1.2711657418728142" CI_START="0.013503014612664989" EFFECT_SIZE="0.1310136236718447" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10420218004885178" LOG_CI_START="-1.869569262357682" LOG_EFFECT_SIZE="-0.8826835411544152" ORDER="1153" O_E="-1.512" SE="1.1594031155958118" STUDY_ID="STD-Sung-1997" TOTAL_1="126" TOTAL_2="124" VAR="0.7439282891566265" WEIGHT="20.48126125752517"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.024305394689188187" CI_END="0.43345831565941384" CI_START="0.04809191362676391" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.14438088473719468" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.3630526609318044" LOG_CI_START="-1.3179279415577367" LOG_EFFECT_SIZE="-0.8404903012447705" METHOD="PETO" MODIFIED="2009-06-29 11:54:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9879208493537306" P_Q="1.0" P_Z="5.598438723197877E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="255" TOTAL_2="213" WEIGHT="100.00000000000001" Z="3.4503578702239017">
<NAME>Recurrent bleeding excluding NSAID users</NAME>
<GROUP_LABEL_1>Eradication tx.</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance antisec.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours eradication</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antisecretor</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9909927400526447" CI_START="0.018378571104021833" EFFECT_SIZE="0.13495566137301152" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.00392952711575843" LOG_CI_START="-1.7356882571371546" LOG_EFFECT_SIZE="-0.8698088921264565" ORDER="1154" O_E="-1.935483870967742" SE="1.0172436503585347" STUDY_ID="STD-Riemann-1997" TOTAL_1="45" TOTAL_2="48" VAR="0.966384653666923" WEIGHT="30.403146349482835"/>
<DICH_DATA CI_END="0.7992107630021884" CI_START="0.03145638189011003" EFFECT_SIZE="0.15855686352751514" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.09733867608214365" LOG_CI_START="-1.5022912313479353" LOG_EFFECT_SIZE="-0.7998149537150395" ORDER="1155" O_E="-2.7039999999999997" SE="0.8252760855904374" STUDY_ID="STD-Santander-1996" TOTAL_1="84" TOTAL_2="41" VAR="1.4682549677419354" WEIGHT="46.19234224511896"/>
<DICH_DATA CI_END="1.2711657418728142" CI_START="0.013503014612664989" EFFECT_SIZE="0.1310136236718447" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10420218004885178" LOG_CI_START="-1.869569262357682" LOG_EFFECT_SIZE="-0.8826835411544152" ORDER="1156" O_E="-1.512" SE="1.1594031155958118" STUDY_ID="STD-Sung-1997" TOTAL_1="126" TOTAL_2="124" VAR="0.7439282891566265" WEIGHT="23.40451140539821"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-06-02 15:38:31 +0100" MODIFIED_BY="Cathy Bennett">
<APPENDIX ID="APP-01" MODIFIED="2009-06-02 15:38:31 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE MODIFIED="2009-01-29 11:58:55 +0000" MODIFIED_BY="Cathy Bennett">MEDLINE Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-06-02 15:38:31 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>10. humans.sh.<BR/>11. 9 and 10<BR/>12. exp peptic ulcer hemorrhage/<BR/>13. exp peptic ulcer perforation/<BR/>14. (bleed$ adj5 ulcer$).tw.<BR/>15. (rebleed$ adj5 ulcer$).tw.<BR/>16. (recurrent adj5 bleed$ adj5 ulcer$).tw.<BR/>17. (acute adj5 bleed$ adj5 ulcer$).tw.<BR/>18. exp gastrointestinal hemorrhage/<BR/>19. (gastrointestinal adj5 bleed$).tw.<BR/>20. (gastrointestinal adj5 rebleed$).tw.<BR/>21. (gastrointestinal adj5 hemorrhag$).tw.<BR/>22. (gastrointestinal adj5 haemorrhag$).tw.<BR/>23. (ulcer adj5 hemorrhag$).tw.<BR/>24. (ulcer adj5 haemorrhag$).tw.<BR/>25. (ulcer adj5 perforat$).tw.<BR/>26. exp helicobacter pylori/<BR/>27. pylori$.tw.<BR/>28. or/12-25<BR/>29. or/26-27<BR/>30. 11 and 28 and 29<BR/>31. limit 30 to yr="2005 - 2008"</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>